Retinoic acid mimetic anilides

ABSTRACT

The present invention is concerned with compounds of formula  
                 
 
     the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR 3 ; R 1  represents hydrogen, hydroxy, C 1-6 alkyl or aryl; R 2  represents hydrogen; optionally substituted C 1-12 alkyl; C 3-7 cycloalkyl; C 2-8 alkenyl; aryl; Het 1 ; or R 1  and R 2  taken together may form a bivalent radical of formula —(CH 2 ) n — wherein n is 2, 3, 4, 5 or 6; R 3  represents hydrogen, optionally substituted C 1-6 alkyl, aryl, Het 1 ; R 4  represents hydrogen; hydroxy; mercapto; C 1-6 alkyloxy; C 1-6 alkylthio; aryloxy; arylthio; Het 1 -oxy; Het 1 -thio; optionally substituted C- 1-12 alkyl; optionally substituted C 2-8 alkenyl; optionally substituted C 2-8 alkynyl; optionally substituted C 3-7 cycloalkyl; optionally substituted C 5-7 cycloalkenyl; aryl; Het 1 ; or —Alk—NR 3 R 5  (i) or —NR 3 R 5  (ii) wherein Alk represents C 1-6 alkanediyl; and R 5  represents hydrogen, C 1-6 alkyl, aryl, Het 1 , (aryl or Het 1 )C 1-6 alkyl, (aryl or Het 1 )carbonyl or (aryl or Het 1 )C 1-6 alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het represents an optionally substituted unsaturated heterocycle; and Het 1  represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.

[0001] The present invention concerns anilides, their N-oxides and addition salts; it further relates to processes for their preparation, compositions comprising them. The compounds of the present invention are potent inhibitors of the retinoic acid metabolism, and hence, their use as a medicine is also described.

[0002] EP-A-0,260,744, published on Mar. 23, 1988, discloses (1H-imidazol-1-ylmethyl) substituted benzimidazoles as inhibitors of the androgen formation from C₂₁-steroids, as inhibitors of the biosynthesis of thromboxane A₂, and also having the capability to increase the excretion of ureic acid. EP-A-0,371,559, published on Jun. 6, 1990, discloses said benzimidazoles and analogous benzotriazoles as potent suppressers of the plasma elimination of endogenously or exogenously administered retinoic acid.

[0003] Retinoic acid (RA) is a key molecule in the regulation of growth and differentiation of epithelial tissues. However, RA is very rapidly metabolized by a series of enzymatic reactions, which results in its deactivation. Inhibition of RA-metabolism leads to enhanced RA levels in plasma and tissue. Therefore, compounds with such an inhibitory action, also called retinoic mimetic activity, have therapeutic and/or preventive potential in the field of dermatology and oncology.

[0004] The present invention is concerned with compounds of formula

[0005] the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein:

[0006] X represents O, S or NR³;

[0007] R¹ represents hydrogen, hydroxy, C₁₋₆alkyl or aryl;

[0008] R² represents hydrogen; C₁₋₁₂alkyl; C₃₋₇cycloalkyl; C₂₋₈alkenyl; aryl; Het¹; or C₁₋₁₂alkyl substituted with one or two substituents selected from C₃₋₇cycloalkyl, hydroxy, C₁₋₄alkyloxy, cyano, amino, mono- and di(C₁₋₄alkyl)amino, mono- or di(arylC₁₋₄alkyl)amino, di(arylC₁₋₄alkyl)aminocarbonyloxy, (C₁₋₄alkyl) (arylC₁₋₄alkyl)amino, mono- and di(aryl)amino, (C₁₋₄alkyl)(di(C₁₋₄alkyl)-aminoC₁₋₄alkyl)amino, pyrrolidinyl, piperidinyl, piperazinyl optionally substituted with C₁₋₄alkyl, morpholinyl, perhydro-azepinyl, carboxyl,

[0009] C₁₋₄alkyloxycarbonyl, aminocarbonyl, mono- and di(C₁₋₄alkyl)aminocarbonyl, aryl, aryloxy and arylthio; or

[0010] R¹ and R² taken together may form a bivalent radical of formula —R¹—R²— wherein —R¹—R²— represents —(CH₂)_(n)— wherein n is 2, 3, 4, 5 or 6;

[0011] R³ represents hydrogen, C₁₋₆alkyl, aryl, Het¹ or C₁₋₆alkyl substituted with aryl or Het¹;

[0012] R⁴ represents hydrogen; hydroxy; mercapto; C₁₋₆alkyloxy; C₁₋₆alkylthio; aryloxy; arylthio; Het¹-oxy; Het¹-thio; C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-oxy, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxy-carbonyl, arylC₁₋₆alkyloxy, arylC₁₋₆alkylthio, aryl, Het¹; C₂₋₈alkenyl optionally substituted with one, two or three substituents selected from halo, C₃₋₇cycloalkyl, aryl, Het¹; C₂₋₈alkynyl optionally substituted with halo, C₃₋₇cycloalkyl, aryl; C₃₋₇cycloalkyl optionally substituted with C₁₋₆alkyl or aryl; C₅₋₇cycloalkenyl optionally substituted with C₁₋₆alkyl or aryl; aryl; Het¹; or

[0013] —Alk—NR³R⁵ (i) or

[0014] —NR³R⁵ (ii)

[0015] wherein Alk represents C₁₋₆alkanediyl; and

[0016] R⁵ represents hydrogen, C₁₋₆alkyl, aryl, Het¹, (aryl or Het¹)C₁₋₆alkyl, (aryl or Het¹)carbonyl or (aryl or Het¹)C₁₋₆alkyloxycarbonyl;

[0017] aryl represents indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl, phenyl; said indanyl, indenyl, naphtyl or phenyl may be substituted with one, two, three, four or five substituents each independently selected from hydroxy, halo, nitro, cyano, amino, azido, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl, polyhaloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, phenyl, phenyloxy, phenylC₁₋₆alkyloxy, pyridinylC₁₋₆alkyloxy, C₁₋₆alkyloxy, formyl, carboxyl and C₁₋₆alkylcarbonyl; or two adjacent carbon atoms on said phenyl may be substituted by a single bivalent radical having the formula C₁₋₁₂alkanediyl or polyhaloC₁₋₁₂alkanediyl;

[0018] Het represents an unsaturated heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl and pyridinyl; each of said unsaturated heterocycles may optionally be substituted with amino, mercapto, C₁₋₆alkyl, C₁₋₆alkylthio or aryl; and

[0019] Het¹ represents a monocyclic heterocycle selected from pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,3,4-triazolyl, 1,2,4-triazolyl, tetrahydrofuranyl, furanyl, thiolanyl, thienyl, dioxolanyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, tetrahydropyranyl, pyranyl, morpholinyl and dioxanyl; each of said monocyclic heterocycles may be optionally substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl; or a bicyclic heterocycle selected from indolinyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, 2H-1-benzopyranyl, 3,4-dihydro-2H-1-benzopyranyl, benzthiazolyl, isoquinolinyl, quinolinyl, 3,4-dihydroquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, chromanyl, 1,4-benzodioxinyl, 1,4-benzoxathianyl, benzodioxanyl and benzodioxolanyl; each of said bicyclic heterocycles may be substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl.

[0020] As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₃₋₇cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C₅₋₇cycloalkenyl is generic to cyclopentenyl, cyclohexenyl and cycloheptenyl; C₂₋₈alkenyl defines straight and branch chained hydro-carbon radicals containing one double bond and having from 2 to 8 carbon atoms such as, for example, ethenyl, l-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl, 3-heptenyl, 2-octenyl and the like; Ci 4alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1 -methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; C₁₋₆alkyl is meant to include C₁₋₄alkyl and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like; C₁₋₁₂alkyl is meant to include C₁₋₆alkyl and the higher homologues thereof having from 7 to 12 carbon atoms such as, for example, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, 2-methylhexyl, 3-ethyloctyl and the like; C₁₋₁₂alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 12 carbon atoms such as, for example, 1,1-methanediyl, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,7-heptanediyl, 1,8-octanediyl, 1,9-nonanediyl, 1,10-decanediyl, 1,11-undecanediyl, 1,12-dodecanediyl, 1,1,4,4-tetra-methylbutane-1,4-diyl and the like; polyhaloC₁₋₆alkyl is defined as polyhalosubstituted C₁₋₆alkyl, in particular C₁₋₆alkyl substituted with 1 to 6 halogen atoms, more in particular difluoro- or trifluoromethyl; polyhaloC₁₋₁₂alkanediyl is defined as polyhalo-substituted C₁₋₁₂alkanediyl, in particular C₁₋₁₂alkanediyl substituted with 1 to 12 halogen atoms; triazolyl is meant to include 1,2,4-triazolyl and 1,3,4-triazolyl; tetrazolyl is meant to include 1H-tetrazolyl and 2H-tetrazolyl; benzodioxanyl is meant to include 2,3-dihydro-1,4-benzodioxinyl.

[0021] The unsaturated heteroaryl group represented by Het may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heteroaryl group is imidazolyl, it may be a 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl; when it is triazolyl, it may be 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,3,4-triazol-1-yl and 1,3,4-triazol-2-yl.

[0022] The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base and acid addition salt forms which the compounds of formula (I) are able to form. The acid addition salt form of a compound of formula (I) that occurs in its free form as a base can be obtained by treating said free base form with an appropriate acid such as an inorganic acid, for example, hydrohalic acid, e.g. hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like acids; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.

[0023] The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic base, i.e. metal or amine, addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

[0024] Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.

[0025] The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

[0026] The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide.

[0027] The term “stereochemically isomeric forms” as used hereinbefore and hereinafter defines all the possible stereoisomeric forms in which the compounds of formula (I) exist. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture, and in particular the racemic mixture, of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. Stereochemically isomeric forms of the compounds of formula (I) and mixtures of such forms are obviously intended to be encompassed by formula (I).

[0028] In particular, some of the compounds of formula (I) and some of the intermediates hereinafter have at least one stereogenic center in their structure. This stereogenic center may be present in a R and a S configuration, said R and S notation is used in correspondance with the rules described in Pure Appl. Chem., 1976, 45, 11-30.

[0029] Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. In particular, compounds of formula (I) wherein R³ is hydrogen may exist in their corresponding tautomeric form.

[0030] Whenever used hereinafter, the term compounds of formula (I) is meant to include also the N-oxides, the pharmaceutically acceptable addition salts and all stereoisomeric forms.

[0031] Whenever used hereinafter, R¹ to R⁴ and Het are defined as under formula (I) unless otherwise indicated.

[0032] A special group of compounds are those compounds of formula (I) wherein one or more of the following restrictions apply:

[0033] (a) X represents O, S, NH or N(aryl); more in particular X is O or S;

[0034] (b) R¹ represents hydrogen, hydroxy or C₁₋₆alkyl;

[0035] (c) R² represents hydrogen; C₁₋₁₂alkyl; C₃₋₇cycloalkyl; C₂₋₈alkenyl; aryl; Het¹; or C₁₋₁₂alkyl substituted with one or two substituents selected from hydroxy, C₁₋₄alkyloxy, cyano, mono- and di(C₁₋₄alkyl)amino, mono- or di(arylC₁₋₄alkyl)-amino, di(arylC₁₋₄alkyl)aminocarbonyloxy, (C₁₋₄alkyl)(arylC₁₋₄alkyl)amino, (C₁₋₄alkyl)(di(C₁₋₄alkyl)aminoC₁₋₄alkyl)amino, piperidinyl, piperazinyl optionally substituted with C₁₋₄alkyl, morpholinyl, C₁₋₄alkyloxycarbonyl, aryl, aryloxy and arylthio; or

[0036] R¹ and R² taken together may form a bivalent radical of formula —R¹—R²— wherein —R¹—R²— represents —(CH₂)_(n)— wherein n is 2;

[0037] (d) R³ represents hydrogen or C₁₋₆alkyl; more in particular R³ is hydrogen;

[0038] (e) R⁴ represents hydrogen; C₁₋₆alkyloxy; aryloxy; C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxycarbonyl, arylC₁₋₆alkylthio, aryl, Het¹; C₂₋₈alkenyl optionally substituted with one, two or three substituents selected from halo, C₃₋₇cycloalkyl, aryl, Het¹; C₂₋₈alkynyl optionally substituted with aryl; C₃₋₇cycloalkyl optionally substituted with C₁₋₆alkyl or aryl; C₅₋₇cycloalkenyl; aryl; Het¹; or

[0039] —Alk—NR³R⁵ (i) or

[0040] —NR³R⁵ (ii)

[0041] wherein Alk represents C₁₋₆alkanediyl; and

[0042] R⁵ represents hydrogen, C₁₋₆alkyl, aryl, Het¹, arylC₁₋₆alkyl, arylcarbonyl or arylC₁₋₆alkyloxycarbonyl.

[0043] Aryl is suitably indenyl, naphtyl, 5,6,7,8-tetrahydro-naphtalenyl, phenyl; said indenyl, naphtyl or phenyl may be substituted with one, two, three, four or five substituents each independently selected from hydroxy, halo, nitro, amino, azido, C₁₋₆alkylcarbonyl-amino, C₁₋₆alkyl, polyhaloC₁₋₆alkyl, phenyl, C₁₋₆alkyloxy.

[0044] Het is suitably imidazolyl, triazolyl and pyridinyl; each of said unsaturated heterocycles may optionally be substituted with C₁₋₆alkyl, more in particular, Het is 1H-1-imidazolyl or 1,2,4-triazol-1-yl.

[0045] Het¹ is suitably pyrrolyl, furanyl, thienyl, isoxazolyl, thiazolyl, piperidinyl, pyridinyl, piperazinyl, pyrimidinyl, pyrazinyl, morpholinyl and dioxanyl; each of said monocyclic heterocycles may be optionally substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl; or indolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, 2H-1-benzopyranyl, 3,4-dihydro-2H-1-benzopyranyl, benzthiazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, 1,4-benzodioxinyl, benzodioxanyl and benzodioxolanyl; each of said bicyclic heterocycles may be substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl.

[0046] Particular compounds are those compounds of formula (I) wherein R² is C₁₋₁₂alkyl optionally substituted with mono- and di(C₁₋₄alkyl)amino, more in particular, R² is 3-pentyl, 2-propyl, 2-(dimethylamino)-ethyl or 2-(diethylamino)-ethyl.

[0047] Other particular compounds are those compounds of formula (I) wherein R⁴ is C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxycarbonyl, arylC₁₋₆alkylthio, aryl, Het¹; aryl; Het¹; or a radical of formula (ii).

[0048] Preferred compounds are those compounds of formula (I) wherein R³ is hydrogen; X is O and R⁴ is aryl or C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxycarbonyl, arylC₁₋₆alkylthio, aryl, Het¹; or a radical of formula (ii).

[0049] Other preferred compounds are those compounds of formula (I) wherein R³ is hydrogen, X is S and R⁴ is a radical of formula (ii).

[0050] More preferred are the compounds of formula (I) wherein X is O; Het is 1,2,4-triazol-1-yl; R¹ and R³ are hydrogen; R² is C₁₋₆alkyl optionally substituted with dialkylamino; and R⁴ is C₁₋₄alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-thio, C₃-₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxycarbonyl, arylC₁₋₆alkylthio, aryl or Het¹.

[0051] Most preferred are 4-chloro-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-α-hydroxybenzeneacetamide; the N-oxides, the pharmaceutically acceptable addition salts and stereoisomeric forms thereof.

[0052] In general, the compounds of formula (I) can be prepared by reacting an intermediate of formula (II) wherein W¹ is an appropriate leaving group such as, for example, a halogen, hydroxy or an alkylsulfonyloxy group, with an intermediate of formula (III) or a functional derivative thereof. For instance, a fumctional derivative of imidazole may be 1,1′-carbonyldiimidazole.

[0053] Said reaction may be performed in a reaction-inert solvent such as, for example, acetonitrile, dichloromethane or tetrahydrofuran, in the presence of a suitable base such as, for example, potassium carbonate. In case W¹ is an hydroxy group, it may be convenient to perform the above reaction in the presence of triphenylphosphine and diethyl azodicarboxylate or a functional derivative of any of said reagents, or in the presence of 1-hydroxy-IH-benzotriazole and dicyclohexylcarbodiimide.

[0054] In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.

[0055] Alternatively, compounds of formula (I) may be prepared by N-alkylation of an intermediate of formula (IV) with an intermediate of formula (V) wherein W² is an appropriate leaving group such as, for example, hydroxy, a phenoxy group or a halogen, in a reaction-inert solvent such as, for example, water, N,N-dimethylformamide, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylacetamide, 2-propanone, benzene or the like, and optionally in the presence of a suitable base such as, for example, triethylamine, pyridine or sodiumcarbonate.

[0056] Also functional derivatives of intermediates of formula (V) may be used such as, for example, an anhydride, e.g. glutaric anhydride, dihydro-2H-pyran-2,6(3H)-dione, acetic acid anhydride; a cyanate; a thiocyanate; an isocyanate or an isothiocyanate. In some instances, it may be convenient to add an acid to the reaction medium such as, for instance, acetic acid may be used together with a cyanate.

[0057] Compounds of formula (I) wherein R⁴ is a Het¹C₁₋₁₂alkyl or a radical of formula (i), said R⁴ being represented by R^(4′) and said compounds being represented by formula (I-a), can be prepared by reacting an intermediate of formula (VI) wherein W³ is a suitable leaving group such as, for example, a halogen, with an intermediate of formula R^(4′)-H (VII) in a reaction-inert solvent such as, for example, acetonitrile, and in the presence of an appropriate base such as, for example, potassium carbonate.

[0058] Compounds of formula (I) wherein R¹ is hydroxy, said compounds being represented by formula (I-b), may be prepared by reacting an intermediate of formula (VIII) with Het-H (III) or a functional derivative thereof, in the presence of an appropriate reagent such as, for example, n-butyllithium, in a reaction-inert solvent such as tetrahydrofuran and diethylether, and optionally in the presence of chlorotriethylsilane.

[0059] Compounds of formula (I) wherein R³ is hydrogen and R⁴ is attached by a nitrogen atom to the remainder of the molecule, said compounds being represented by formula (I-c), may be prepared by reacting a primary or secundary amine of formula (VIII) with an intermediate of formula (IX) in a reaction-inert solvent such as, for example, acetonitrile.

[0060] Compounds of formula (I) wherein R² is optionally substituted hydroxymethyl, being represented by formula (I-d), may be prepared by reacting an intermediate of formula (XI) with Het-H (XII) or a functional derivative thereof, in a reaction-inert solvent such as, for example N,N-dimethylformamide.

[0061] Compounds of formula (I) can also be prepared by reacting an intermediate of formula (XIII) wherein W⁴ is a suitable leaving group such as, for example, hydroxy, with an intermediate of formula (XIV) in an appropriate solvent such as, for example, acetic acid, and in the presence of an acid such as, for example, concentrated sulfuric acid.

[0062] Compounds of formula (I) wherein R² is C₁₋₄alkyloxyC₁₋₁₂alkyl can be prepared by reacting an intermediate corresponding to a compound of formula (I) wherein R² is LG-C₁₋₁₂alkyl wherein LG is an appropriate leaving group such as, for example, a alkylsulfonyloxy group, with C₁₋₄alkylO⁻M⁺ wherein M⁺ is a suitable metal ion such as, for example Na⁺, in a suitable solvent such as methanol.

[0063] Compounds of formula (I) wherein R2 is optionally substituted C₁₋₁₂alkyl, said R² being represented by R^(2′) and said compounds being represented by formula (I-e), can be prepared by reducing an intermediate of formula (XV) using a suitable reducing agent such as, for example, sodiumborohydride, in a suitable solvent such as methanol.

[0064] Compounds of formula (I) wherein R¹, R³ and R⁴ are hydrogen, said compounds being represented by formula (I-f), can be prepared by reacting an intermediate of formula (XXIII) with formamide in the presence of an acid such as, for example, acetic acid.

[0065] The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation.

[0066] For example, compounds of formula (I) wherein R³ is hydrogen may be converted to compounds of formula (I) wherein R³ is other than hydrogen using art-known techniques.

[0067] Compounds of formula (I) containing an aliphatic double bond may be converted to compounds of formula (I) wherein said aliphatic double bond is reduced to a single bond using art-known hydrogenation techniques such as, for example, a reaction with hydrogen in methanol in the presence of palladium on activated charcoal as catalyst.

[0068] Compounds of formula (I) containing a carboxyl group may be esterified using art-known esterification techniques. Conversely, compounds of formula (I) containing ester may be hydrolysed to compounds of formula (I) containing the corresponding carboxyl moiety.

[0069] Also, compounds of formula (I) containing a C₁₋₆alkyloxycarbonyl substituent, may be transformed to compounds of formula (I) wherein said substituent is reduced to hydroxymethyl using for instance, lithium aluminium hydride in tetrahydrofuran; and if desired, said hydroxymethyl substituent may be further transformed to a formyl group. Said C₁₋₆alkyloxycarbonyl may also be entirely removed. Analogously, other moieties which may serve the purpose of protective group such as, for example, phenylmethyl, may also be removed using art-known techniques.

[0070] Compounds of formula (I) wherein R¹ is hydroxy can be converted to compounds of formula (I) wherein R¹ is hydrogen using a suitable reagent such as stannous chloride.

[0071] Compounds of formula (I) wherein R⁴ is a phenoxy group may be converted to the ureum derivatives thereof using art-known replacement techniques. For instance, a primary or secundary amine may be used optionally in the presence of dimethylamino-pyridine and a base such as triethylamine, and 1,4-dioxane may be used as solvent.

[0072] Compounds of formula (I) wherein X is O may be converted to compounds of formula (I) wherein X is S using art-known techniques such as, for example, the use of phosphorous pentasulfide in pyridine.

[0073] The compounds of formula (I) may also be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

[0074] Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.

[0075] An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase such as, for example, a Chiracel AD column.

[0076] Some of the intermediates and starting materials are known compounds, may be commercially available or may be prepared according to art-known procedures.

[0077] In particular, intermediates of formula (II) wherein R¹ is hydrogen and W¹ is hydroxy, said intermediates being represented by formula (II-1), may be prepared by reducing a ketone of formula (VIII). The reduction may be performed in the presence of a suitable reducing agent in an appropriate reaction-inert solvent such as, for example, sodium-borohydride in methanol or lithiumaluminiumhydride in tetrahydrofuran and water.

[0078] In some instances, it may be convenient to replace the hydroxy group in intermediates of formula (II-1) by another leaving group such as, for example, a halogen or a sulfonyl derivative, e.g. a p-toluenesulfonyloxy group or a alkylsulfonyloxy group, thus forming intermediates of formula (II-2) or (II-3). Said reaction can be performed in a reaction-inert solvent, such as, for example, chloroform, and in the presence of a suitable reagent such as, for example, thionylchloride or methylsulfonyl chloride.

[0079] Intermediates of formula (IV) may be prepared by reacting an intermediate of formula (XVI), wherein P is a protective group such as, for example, C₁₋₄alkylcarbonyl, benzoyl or C₁₋₄alkyloxycarbonyl, with an intermediate of formula (III), and by subsequently reacting the thus formed amide derivative with an acid such as, for example, hydrochloric acid. The preparation of the intermediate amide derivative may be performed using the same procedure as the one used for the preparation of compounds of formula (I) starting from an intermediate of formula (II) and (III).

[0080] Intermediates of formula (IV) wherein R³ is hydrogen, said intermediates being represented by formula (IV- 1), may be prepared by reducing a nitro derivative of formula (XVII). Said reduction may be performed in the presence of a suitable reducing agent such as, for example, hydrogen, in an appropriate solvent such as, for example, methanol and in the presence of a suitable catalyst such as, for example, raney nickel.

[0081] Intermediates of formula (VI) can be prepared by further reacting an intermediate of formula (IV) with an intermediate of formula (XVIII) wherein W³ is a suitable leaving group such as, for example, a halogen, in a reaction-inert solvent such as, for example, dichloromethane, and in the presence of a base such as, for example, sodium carbonate.

[0082] Intermediates of formula (X) may be prepared by reacting an intermediate of formula (IV-1) with a reagent of formula (XIX) in a reaction inert solvent such as, for example, dichloromethane, and in the presence of a suitable base such as, for example, sodium hydroxide.

[0083] Intermediates of formula (XI) may be prepared by reductively reacting intramolecularly an intermediate of formula (XX) wherein W⁴ is a suitable leaving group such as, for example, a halogen in the presence of a suitable reagent such as, for example, sodium-borohydride, in a reaction inert solvent such as, for example, methanol, and in the presence of a suitable base such as, for example, sodium hydroxide.

[0084] Intermediates of formula (XI) can be prepared by first dehydrating and deprotecting an intermediate of formula (XXI) wherein P is a protecting group such as, for example, C₁₋₄alkylcarbonyl, benzoyl or C I4alkyloxycarbonyl, using a suitable reagent such as, for example, an acid, e.g. hydrochloric acid, thus forming an intermediate of formula (XXII). Consequently, said intermediate of formula (XXII) may be further reacted with an intermediate of formula (V) in the same manner as described for the reaction between intermediates (IV) and (V).

[0085] Intermediates of formula (XXI) can be prepared by first reacting an intermediate of formula (XXIV) with Het-H (III) or a functional derivative thereof, in the presence of an appropriate reagent such as, for example, n-butyllithium, in a reaction-inert solvent such as tetrahydrofuran and diethylether, and optionally in the presence of chlorotriethylsilane. The thus formed nitro derivative of formula (XXV) may then be reduced using for example a 15% solution of TiCl₃ in water as reducing agent in a suitable solvent such as, for example, tetrahydrofuran.

[0086] The compounds of formula (I) suppress the plasma elimination of retinoids, such as all-trans-retinoic acid, 13-cis retinoic acid and their derivatives, resulting in more sustained plasma and tissue concentrations of retinoic acid and improved control of the differentiation and growth of various cell types. This action of the present compounds is also called retinoic mimetic activity because administering a compound of formula (I) causes the same effect as if retinoids were administered. As such, the present compounds can be used to control the rate of growth and differentiation of normal, preneoplastic and neoplastic cells, whether they are epithelial or mesenchymal; whether they are of ectodermal, endodermal or mesodermal origin.

[0087] The property to delay the metabolism of retinoic acid can be evidenced in various in vitro and in vivo experiments. A particular in vitro procedure is described in example C.1 and tests the inhibitory activity of the compounds of formula (I) on the metabolism of retinoic acid in human breast cancer cells. The compounds of the present invention were also effective in suppressing induced vaginal keratinization effects in ovariectomized rats as is described in example C.2.

[0088] In addition, the compounds of formula (I) show little or no endocrinological side-effects and they have good oral availability.

[0089] In view of the above described pharmacological properties, in particular their retinoic mimetic activity, the present compounds are useful in the treatment and/or the prevention of disorders characterized by abnormal proliferation and/or abnormal differentiation of cells, in particular of cells of which the growth and differentiation is sensitive to the actions of retinoids. Such disorders are situated in the field of oncology, for example, head- and neck cancer, lung cancer, breast cancer, uterine cervix cancer, gastrointestinal tract cancer, skin cancer, bladder cancer and prostate cancer and similar disorders; and in the field of dermatology, for example, keratinization disorders such as rosacea, acne, psoriasis, severe psoriasis, lamellar ichthyosis, plantar warts, callosities, acanthosis nigricans, lichen planus, molluscum, melasma, corneal epithelial abrasion, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, melasma, hyperpigmentation and similar disorders.

[0090] Further, the compounds of formula (I) are useful in suppressing the metabolism of exogenously administered and of endogenously formed 1α,25-dihydroxy-vitamin D₃ (calcitriol). The inhibitory activity of the compounds of formula (I) on the metabolic degradation of calcitriol may be evidenced by measuring the impact of said compounds on the calcitriol degradation in human foreskin keratinocytes, pig kidney cells and human hepatoma cells. In view of their inhibitory effect on the calcitriol metabolism, the compounds of formula (I) can be used in the treatment of vitamin D deficiency states. The “classic” application of vitamin D compounds lies in the field of metabolic bone disorders. Calcitriol has also been described to influence the effects and/or production of interleukins. Further, calcitriol is of use in the treatment of diseases characterized by abnormal cell proliferation and/or differentiation, in particular, keratinization disorders such as those described hereinabove (Bouillon et al., Endocrine Reviews, 1995, 16, 200-257).

[0091] In view of the above described uses of the compounds of formula (I), it follows that the present invention provides a method of treating warm-blooded animals suffering from diseases which are characterized by an abnormal proliferation and/or abnormal differentiation of normal, preneoplastic or neoplastic cells, whether they are epithelial or mesenchymal; whether they are of ectodermal, endodermal or mesodermal origin. Said method comprises the systemic or topical administration of a retinoic mimetic amount of a compound of formula (I) effective in treating the above described disorders, in particular oncology disorders and keratinization disorders, optionally in the presence of an effective amount of a retinoic acid, a derivative or a stereochemically isomeric form thereof. The present invention further concerns a method of treating patients suffering from a pathological condition which may be beneficially influenced by the administration of calcitriol or a prodrug thereof, in particular oncology disorders and keratinization disorders, said method consisting of administering to a patient (a) an effective amount of calcitriol or a prodrug thereof and (b) an effective amount of a compound of formula (I).

[0092] The compounds of formula (I) may conveniently be used in combination with a chemotherapeutic agent, in particular an anti-neoplastic agent such as, e.g. daunorubicin, doxorubicin, vincristine, vinblastine, etoposide, taxol, taxotere, dactinomycin, mitoxantrone, mitomycin, trimetrexate and the like. The combination may be administered separately, simultaneously, concurrently or consecutively, or the combination may also be presented in the form of one pharmaceutical formulation. Thus, the present invention also involves a pharmaceutical product comprising (a) a compound of formula (I) and (b) a chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the therapeutic or prophylactic treatment of warm-blooded animals suffering from disorders characterized by abnormal proliferation and/or abnormal differentiation of cells. Such a product may comprise a kit comprising a container containing a pharmaceutical composition of a compound of formula (I), and another container comprising a pharmaceutical composition of the chemotherapeutic agent. The product with separate compositions of the two active ingredients has the advantage that appropriate amounts of each component, and timing and sequence of administration can be selected in function of the patient. The present invention further concerns a method of treating patients suffering from disorders characterized by abnormal proliferation and/or abnormal differentiation of cells, said method consisting of administering to a patient (a) an effective amount of a compound of formula (I) and (b) an effective amount of a chemotherapeutic agent.

[0093] Thus, the present invention also relates to compounds of formula (I) as defined hereinabove for use as a medicine, in particular, for use in the manufacture of a medicament for the treatment of oncology disorders and keratinization disorders. The present invention further relates to compounds of formula (I) as defined hereinabove in combination with a retinoic acid, a derivative or a stereochemically isomeric form thereof, or in combination with calcitriol or a prodrug thereof, or in combination with a chemotherapeutic agent, in particular an anti-neoplastic agent, for use as a medicine.

[0094] For ease of administration, the subject compounds may be formulated into various pharmaceutical forms. As appropriate compositions there may be cited all compositions usually employed for systemically or topically administering drugs. To prepare the pharmaceutical compositions of this invention, a retinoic mimetic effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g. as a transdermal patch, as a spot-on or as an ointment. Addition salts of compounds of formula (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

[0095] As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. Application of said compositions may be by aerosol, e.g. with a propellent such as nitrogen, carbon dioxide, a freon, or without a propellent such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular compositions, semisolid compositions such as salves, creams, gelies, ointments and the like will conveniently be used.

[0096] It is especially advantageous to formulate the aforementioned pharmaceutical composi- tions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (included scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

[0097] Other such compositons are preparations of the cosmetic type, such as toilet waters, packs, lotions, skin milks or milky lotions. Said preparations contain, besides the active ingredient, components usually employed in such preparations. Examples of such components are oils, fats, waxes, surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols, and the like. If desired, further ingredients may be incorporated in the compositions, e.g. antiinflamatory agents, antibacterials, antifungals, disinfectants, vitamins, sunscreens, antibiotics, or other anti-acne agents.

[0098] The present invention also provides particular pharmaceutical or cosmetical compositions which comprise a pharmaceutically acceptable carrier, an effective amount of a compound of formula (I) and an effective amount of a retinoic acid, a derivative thereof or a stereochemically isomeric form thereof. Said retinoic acid containing compositions are particularly useful for treating acne or for retarding the effects of aging of the skin and generally improve the quality of the skin, particularly human facial skin.

[0099] Further, the invention also relates to particular pharmaceutical or cosmetical compositions which comprise a pharmaceutically acceptable carrier, an effective amount of a compound of formula (I) and an effective amount of calcitriol or a prodrug thereof. The latter compositions are particularly useful in treating keratinization disorders.

[0100] The invention also relates to a product containing retinoic acid or a derivative thereof and a compound of formula (I) as a combined preparation for simultaneous, separate or sequential use in dermatological or oncological disorders. The invention also relates to a product containing calcitriol or a prodrug thereof and a compound of formula (I) as a combined preparation for simultaneous, separate or sequential use in dermatological or oncological disorders. Such products may comprise, for example, a kit comprising a container with a suitable composition containing a compound of formula (I) and another container with a composition containing calcitriol or a retinoid Such a product may have the advantage that a physician can select on the basis of the diagnosis of the patient to be treated the appropriate amounts of each component and the sequence and timing of the administration thereof.

[0101] Those of skill in the treatment of the disorders described hereinabove could determine the effective therapeutic daily amount from the test results presented in the experimental part. An effective therapeutic daily amount would be from about 0.01 mg/kg to about 40 mg/kg body weight, more preferably from about 0.1 mg/kg to about 10 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose once daily or as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.1 mg to 500 mg of active ingredient per unit dosage form.

[0102] The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines. The following examples are intended to illustrate the scope of the present invention.

Experimental part

[0103] Of some compounds of formula (I) the absolute stereochemical configuration of the stereogenic carbon atom(s) therein was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as “A” and the second as “B”, without further reference to the actual stereochemical configuration. Said “A” and “B” forms of those compounds of formula (I) wherein two asymmetric carbon atoms are present were separated in their pure steroechemically isomeric forms and designated as “A1” and “A2”, and “B1” and “B2”, without further reference to the actual stereochemical configuration.

[0104] As used hereinafter, “THF” is defined as tetrahydrofuran, “EtOAc” is defined as ethylacetate, “DIPE” is defined as dilsopropyl ether and “RT” is defined as room temperature.

A) Preparation of the intermediate compounds EXAMPLE A1

[0105] Methanesulfonyl chloride (0.308 mol) was added dropwise to a solution of N-[4-(1 -hydroxy-2-methylpropyl)phenyl] acetamide (0.1514 mol) and triethylamine (0.308 mol) in CH₂Cl₂(600 ml) and the mixture was stirred at 0° C. for 1 hour. The solvent was evaporated, yielding 44 g (100%) of (±)-4-(acetylamino)-α-(1-methylethyl) benzenemethanol methanesulfonate(ester) (intern. 1).

EXAMPLE A2

[0106] A mixture of (±)-N-[4-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]phenyl]acetamide (0.095 mol) in HCl (3N) (250 ml) was stirred and heated at 60° C. for 5 hours. The mixture was cooled, poured into ice, basified with concentrated NH₄OH and extracted with CH₂Cl₂. The organic layer was dried, filtered off and evaporated. The residue was crystallized from 2-propanone/(C₂H₅)₂O and filtered off, yielding 15.5g (75%) of (±)-4-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]-benzenamine (interm. 2; mp. 117.8° C.).

[0107] In a similar manner were also prepared:

[0108] (A)-4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]benzenamine (interm. 3);

[0109] (B)-4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]benzenamine (interm. 4); and

[0110] (±)-4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]benzenamine (interm. 5).

EXAMPLE A3

[0111] 1,2-Dichloroethanone (0.027 mol) was added dropwise at RT to a solution of interme diate (5) (0.0246 mol) in sodium carbonate (10%) (450ml) and CH₂Cl₂ (600ml). The mixture was stirred for 3 hours and then extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 7g (89%) of (±)-2-chloro-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]acetamide (inter. 6).

EXAMPLE A4

[0112] a) (±)-4-(2-methyl-3-phenylpropyl)pyridine (0.114 mol) was added portionwise at 0° C. to sulfonic acid (63 ml), the mixture was stirred at 0° C. for 1 hour and then at RT for 2 hours. The mixture was poured into ice, basified with NH₄OH and the precipitate was filtered off, yielding 29.31g (100%) of (±)-4-[2-methyl-1-(4-nitrophenyl)propyl]-pyridine (interm. 7).

[0113] b) Intermediate (7) (0.183 mol) in methanol (470 ml), NH₄OH (47 ml) and a solution of thiophene in methanol (4%; lml) was hydrogenated at RT with palladium on activated carbon (10%; 7.7 g) as a catalyst over a 2 hour period under a 3 bar pressure in a Parr apparatus. After uptake of hydrogen, the catalyst was filtered through celite and the filtrate was evaporated, yielding 42.79 g of product. A sample (3g) was taken up in CH₂Cl₂ and purified on a glass filter over silica gel (eluent: CH₂Cl₂/CH₃OH 99.5/0.5). The pure fractions were collected and evaporated. The residue was purified further by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97.5/2.5/0.1). The pure fractions were collected and evaporated. The residue was recrystallized from (C₂H₅)₂O and filtered off, yielding 0.86g of (±)-4-[2-methyl-1-(3-pyridinyl)propyl]benzenamine (interm. 8; mp. 101.5° C).

EXAMPLE A5

[0114] a) A mixture ofN-[4-(2-chloro-1-oxopropyl)phenyl]acetamide (0.19 mol), N-methyl-methanamine hydrochloride (1:1)(0.38 mol) and K₂CO₃ (78.8 g) in CH₃CN (1400 ml) was stirred and refluxed for 12 hours. The mixture was cooled, poured into water and extracted with CH₂Cl₂. The organic layer was dried, filtered and the solvent was evaporated, yielding 39.77 g (89%) of (±)-N-[4-[2-(dimethylamino)-1-oxopropyl]phenyl]-acetamide (intern. 9).

[0115] b) Sodium tetrahydroborate (2.6 mol) was added portionwise at 0° C. under N₂ flow to a mixture of intermediate (9) (2.18 mol) in methanol (5000 ml). The mixture was stirred for 1 hour, poured out into ice water (5000 ml) and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was stirred in DIPE, filtered off and dried, yielding 357 g (70%) of (±)-N-[4-[1-hydroxy-2-(dimethylami no)propyl]phenyl]acetamide (intenrm. 10).

EXAMPLE A6

[0116] Sodium tetrahydroborate (0.0502 mol) was added portionwise at 0° C. to a mixture of (±)-N-[4-(2-chloro-l-oxopropyl)phenyl]-3,4-dimethoxybenzeneacetamide (0.0502 mol) in methanol (280 ml). The mixture was stirred at 0° C. for 1 hour, then poured out into a mixture of NaOH (280 ml) and ice, stirred for 1 hour and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 15.48 g (94%) of (±)-3,4-dimethoxy-N-[4-(3-methyl-2-oxiranyl)phenyl]benzeneacetamide (interm. 11).

EXAMPLE A7

[0117] a) n-Buthyl-lithium in hexane (1.6M; 71.6 ml) was added dropwise at −70° C. under N₂ flow to a mixture of 1-methylimidazole (0.1146 mol) in THF (195 ml). The mixture was stirred at −70° C. for 30 minutes. Chlorotrietylsilane (0.1146 mol) was added. The mixture was brought slowly to 10° C. and cooled again to −70° C. n-Buthyl-iithium in hexane (1.6M; 71.6 ml) was added dropwise. The mixture was stirred at −70° C. for 1 hour, brought to −15° C. and cooled again to −70° C. A mixture of 4-chlorophenyl-4-nitrophenyl-methanone (0.095 mol) in THF (150 ml) was added dropwise. The mixture was stirred at −70° C. for 30 minutes, hydrolized and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.1). The desired fractions were collected and their solvents were evaporated, yielding 6.5g (20%) of (±)-α-(4-chlorophenyl)-1-methyl-α-(4-nitrophenyl)-1H-imidazole-2-methanol (interm 12), 8.7 g (26.6%) of (±)-α-(4-chlorophenyl)-1-methyl-α-(4-nitrophenyl)-1H-imidazole-5-methanol (interm 13) and 18 g (53%) of the mixture of intermediate 12 and 13.

[0118] b) A mixture of intermediate 12 and 13 (0.09 mol) in THF (600 ml) was cooled on an ice bath. TiCl₃ in H₂O (15%; 400 ml) was added dropwise quickly. The mixture was stirred at RT for 90 minutes, poured out on ice, alkalized with NaOH 10N, then filtered over celite, pasted up and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 94/6). Two pure fractions were collected and their solvents were evaporated. Both residues were crystallized from CH₃CN and DIPE. Each phe precipitate was filtered off and dried, yielding 2g (7.1 %) of (±)-α-(4-aminophenyl)-α-(4-chlorophenyl)-1-methyl-1H-imidazole-2-methanol (interm. 14) and 1.5g (5.3%) of (±)-α-(4-aminophenyl)-α-(4-chlorophenyl)-1-methyl-1H-imidazole-5-methanol (interm. 15).

[0119] B) Preparation of the compounds of formula (I)

EXAMPLE B1

[0120] A mixture of (±)-4-(acetylamino)-α-(1-methylethyl)benzenemethanol methane sulfonate (ester) (0.1541 mol), 1H-1,2,4-triazole (0.308 mol) and K₂CO₃ (0.308 mol) in CH₃CN (500 ml) was stirred and refluxed for 12 hours. The solvent was evaporated and the residue was taken up in water/CH₂Cl₂. The organic layer was dried, filtered off and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and evaporated, yielding 10 g (25%) of (±)-N-[4-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]-phenyl]acetamide (compound 153).

EXAMPLE B2

[0121] A solution of 2-methyl-3-phenyl-2-propenoyl chloride (0.0554 mol) in CH₂Cl₂ (50 ml) was added dropwise to a solution of (±)-4-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]-benzenamine (0.037 mol) in pyridine (8ml) and CH₂Cl₂ (100 ml) and the mixture was stirred at RT for 4 hours. The solvent was evaporated and the residue was taken up in water/EtOAc. The organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1). The pure fractions were collected and evaporated. The residue was crystallized from (C₂H₅)₂O/methylethylketone, yielding 2.7g (21%) of (±)-(E)-2-methyl-N-[4-[2-methyl-1-(1H-1,2,4-triazol- 1 -yl)propyl]phenyl]-3-phenyl-2-propenamide (compound 154).

EXAMPLE B3

[0122] A mixture of 1-hydroxy-1H-benzotriazole (0.0227 mol) in THF (90 ml) was added dropwise at 5° C. under N₂ flow to a solution of (A)-4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]benzenamine (0.015 mol) and (±)-4-chloro-α-hydroxybenzeneacetic acid (0.0227 mol) in THF (95 ml). A mixture of N,N-methanetetraylbis[cyclohexanamine] (0.0227 mol) in CH₂Cl₂ (37 ml) was added dropwise at 5° C. under N₂ flow. The mixture was stirred at RT for 15 hours. The precipitate was filtered off and washed with CH₂Cl₂. The filtrate was taken up in K₂CO₃ 10% and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (9.25 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 96/4). The pure fractions were collected and the solvent was evaporated, yielding 4.8g (78%) of (±)-(A)-4-chloro-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]-phenyl]-α-hydroxybenzeneacetamide (compound 16).

EXAMPLE B4

[0123] (±)-(E)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]-2-methyl-3-phenyl-2-propenamide (0.0144 mol) in methanol (200 ml) was hydrogenated with palladium-on-charcoal 10% (0.52g) as a catalyst at RT over a 5 hour period under a 1 bar pressure in a Parr apparatus. After uptake of hydrogen, the catalyst was filtered through celite and the solvent was evaporated. The residue was crystallized from 2-butanone/DIPE, yielding 4.9 g (94%) of (±)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]-α-methyl-benzenepropanamide (compound 164).

EXAMPLE B5

[0124] A mixture of 4-[1-(1H-imidazol-1-yl)-2-methylpropyl]benzenamine (0.0185 mol) in formic acid (20 ml) was stirred and heated at 120° C. for 15 minutes. The mixture was poured into water, basified with NaOH 3N and extracted with EtOAc. The organic layer was dried, filtered off and the solvent evaporated, yielding 3.9 g (86.6%) of (±)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]formamide (compound 177).

EXAMPLE B6

[0125] a) A mixture of 4-[1-(1H-imidazol-1-yl)-2-methylpropyl]benzenamine (0.023 mol) and dihydro-2H-pyran-2,6(3H)-dione (0.03 mol) in THF (200ml) was stirred and refluxed for 12 hours. When the reaction was complete, the solvent was evaporated, yielding 7.5 g (±)-5-[[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]amino]-5-oxopentanoic acid (compound 218).

[0126] b) A mixture of (compound 218) (0.023 mol) in ethanol (200 ml) and H₂SO₄ (3 ml) was stirred and refluxed for 12 hours. When the reaction was complete, the solvent was evaporated, the residue was taken up in water and extracted with CH₂Cl₂. The organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 97/3/0.1). The pure fractions were collected and evaporated. The residue was crystallized from 2-butanone and DIPE, yielding 1.45 g (18%) of (±)-ethyl 5-[[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]amino]-5-oxopentanoate (compound 219).

EXAMPLE B7

[0127] A mixture of (A)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]4-nitrobenzene-acetamide (0.0005 mol) in methanol (50 ml) was hydrogenated at RT (p=2 bar) for 4 hours with Raney Nickel (0.2 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off over celite, washed with CH₃OH and the solvent was evaporated. The residue (0.12 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96.5/3.5/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.035 g (19%) of (A)-4-amino-N-[4-[l -(1H-imidazol-1-yl)-2-methylpropyl]phenyl]benzeneacetamide (compound 145).

EXAMPLE B8

[0128] A solution of NaNO₂ (0.0023 mol) in water (6 ml) was added at 0° C/−5° C. to a solution of (B)-4-amino-N-[4-[1-[(1H-imidazol-1-yl)-2-methylpropyl]phenyl]-3-iodobenzeneacetamide (0.0021 mol) in HC; 2N (17 ml). The mixture was stirred at 0° C. for 15 minutes. A solution of NaN₃ (0.0023 mol) in water (6 ml) was added. The mixture was stirred at 0° C. for 2 hours, then neutralized with K₂CO₃ 10% and extracted with CH₂C1₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-butanone and DIPE. The precipitate was filtered off and dried, yielding 0.46 g (44%) (B)-4-azido-N-[4-[1-(1H-imidazol-1-yl)-2-methyl-propyl]phenyl]-3-iodobenzenacetamide (compound 259).

EXAMPLE B9

[0129] A mixture of (±)-2-chloro-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]acetamide (0.0218 mol), 1-methylpiperazine (0.0436 mol) and K₂CO₃ (0.0436 mol) in CH₃CN (150 ml) was stirred and refluxed for 4 hours. The mixture was cooled, poured out into water and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (8.13 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 3g (35.8%) (±)-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-4-methyl-1-piperazineacetamide (compound 15).

EXAMPLE B10

[0130] Compound (16) (0.0116 mol) was separated into its enantiomers by column chromatography (eluent: hexane/2-propanol 50/50; column: CHIRACEL OD 20 μm). Two pure fractions were collected and their solvents were evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 1.77 g (35%) (±)-A1-4-chloro-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-α-hydroxybenzeneacetamide (compound 17) and 1.72 g (42%) (±)-(A2)-4-chloro-N-[4-[2-ethyl)-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-α-hydroxybenzeneacetamide (compound 18).

EXAMPLE B 11

[0131] HCl conc. (3.6 ml) was added at RT to a mixture of (±)-1,1-dimethylethyl 4-[[[4-[2-ethyl-1-(1H-imidazol-1-yl)butyl]phenyl]amino]carbonyl]- 1 -piperidinecarboxylate (0.0032 mol) in EtOAc (30ml). The mixture was stirred at RT for 4 hours, then basified with a concentrated NaOH solution and extracted with EtOAc and then CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (1 g) was converted into the hydrochloric acid salt (1:1) in 2-propanol. The precipitate was filtered off and dried, yielding 0.85g (68%) (±)-N-[4-[2-ethyl-1-(1H-imidazol-1-yl)butyl]-phenyl]-4-piperidinecarboxamide monohydrochloride (compound 57).

EXAMPLE B12

[0132] A mixture of a-(4-chlorophenyl)-3-pyridinemethanol (0.364mol) and N-phenyl acetamide (0.364 mol) in HOAc (360 ml) and H₂SO₄ 36N (38.6 ml) was stirred and refluxed for 6 days. The solvent was evaporated, yielding 122.6 g (±)-N-[4-[(4-chloro-phenyl)(3-pyridinyl)methyl]phenyl]acetamide (compound 673).

EXAMPLE B 13

[0133] Butyllithium, 1.6M in hexane (146ml) was added dropwise at −78° C. under N₂ flow to a solution of 2-bromopyridine (0.1348 mol) in THF (300ml). The mixture was stirred at −78° C. for 20 minutes. A solution of N-(4-formylphenyl) acetamide (0.1226 mol) in THF (300 ml) was added at −60° C./−70° C. The mixture was stirred at −60° C./−70° C. for 1 hour, then poured out into ice water and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (27 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether and 2-propanone. The precipitate was filtered off and dried, yielding 5.09 g (17%) (±)-N-[4-[hydroxy(2-pyridinyl)methyl]phenyl]-acetamide (compound 688).

EXAMPLE B14

[0134] To a solution of 4-[2-methyl-1-(3-pyridinyl)propyl]benzenamine (0.187 mol) into CH₂Cl₂ (400 ml) was added dropwise Al₂O (100 ml). The mixture was stirred for 24 hours at RT. The mixture was hydrolyzed by H₂O and neutralized by NH₄OH. The organic layer was washed with water and dried. The filtrate was evaporated, yielding 50 g of N-[4-[2-methyl-1-(3-pyridinyl)propyl]phenyl]acetamide (compound 671).

EXAMPLE B15

[0135] 1H-1,2,4-triazole (0.19 mol) and triphenylphosphine (0.19 mol) were added to a mixture of (±)-N-[4-[1-hydroxy-2-(dimethylamino)propyl]phenyl]acetamide (0.1269 mol) in THF (300 ml). The mixture was cooled to 0° C. Diethyl 1,2-hydrazinedicarboxylate (0.19 mol) was added dropwise. The mixture was stirred at RT overnight. The solvent was evaporated and the residue was taken up in EtOAc and HCl 1N was added. The mixture was separated into its layers. The aqueous layer was washed with EtOAc, basified with a K₂CO₃ solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 93/7/0.1 and 80/20/0.1). Two pure fractions were collected and their solvents were evaporated. The desired fraction was recrystallized from 2-propanone/EtOAc. The precipitate was filtered off and dried, yielding 1.2 g of (±)-(B)-N-[4-[2-(dimethylamino)-1-(1H-1,2,4-triazol-1-yl)propyl]phenyl] acetamide (compound 631).

EXAMPLE B16

[0136] A mixture of (±)-(E)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]-2-[(4-nitrophenyl)-methylene]propanamide (0.00742 mol) in THF (80ml) and TiCl₃ (30ml) was stirred at 0° C. for 15 minutes. The mixture was poured into water, ice and NaOH 3N and extracted with CH₂Cl₂ (2×100 ml). The combined organic layers were dried, filtered and the solvent evaporated. The residue was taken up in CH₂Cl₂ and (C₂H₅)₂O. The precipitate was filtered off and stirred K₂CO₃ 10% and CH₂Cl₂, dried, filtered off and evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off, taken up in Na₂CO₃ 10% and CH₂Cl₂. The organic layer was dried, filtered off and evaproated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.1). The pure fractions were collected and evaporated. The residue was crystallized from (C₂H₅)₂O, yielding 1.5 g (±)-(E)-2-[(4-aminophenyl)methylene]-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]propanamide (compound 61 1).

EXAMPLE B 17

[0137] 1,1′-Carbonyldiimidazole (0.236 mol) was added at 60° C. to a solution of (±)-N-[4-[1-hydroxy-2-methylpropyl]phenyl]acetamide (0.115 mol) in tetrahydrofuran (240 ml) and the mixture was stirred at 60° C. for 12 hours. The solvent was evaporated and the residue was taken up in water/CH₂Cl₂. The organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and evaporated. The residue was crystallized from 2-propanone, yielding 28.27 g (67%) (±)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl] acetamide (compound 521).

EXAMPLE B 18

[0138] LiAlH₄ (0.0117 mol) was added portionwise at 0° C. to a solution of (±)-ethyl (A)-β-[4-[[(3,4-dimethoxyphenyl)acetyl]amino]phenyl]-α-methyl-1H-imidazol-1-propanoate (0.0117 mol) in THF (78 ml). The mixture was allowed to warm to RT overnight and then cooled to 0° C. LiAlH₄ (0.0117 mol) was added portionwise at 0C. The mixture was allowed to warm to RT, then stirred at RT for 2 hours, poured out on ice and filtered over celite. The filtrate was extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.1 and 90/10/0.2). Two pure fractions (F1 and F2) were collected and their solvents were evaporated. F1 was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 0.9 g (±)-(A)-3,4-dimethoxy-N-[4-[1-(1H-imidazol-1 -yl)-2-(hydroxy-methyl)propyl]phenyl]benzeneacetamide (19%) (compound 386). F2 was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.2). The pure fractions were collected and the solvent was evaporated. The residue was purified by column chromatography over amino phase (eluent: CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated, yielding 0.5 g (±)-(B)-3,4-dimethoxy-N-[4-[1-(1H-imidazol-1-yl)-2-(hydroxymethyl)propyl]phenyl]-benzeneacetamide (10%) (compound 394).

EXAMPLE B 19

[0139] A mixture of (±)-3,4-dimethoxy-N-[4-[1-(1H-imidazol-1-yl)-2-[methyl(phenylmethyl)-amino]propyl]phenyl]benzenacetamide (0.0066 mol) in ethanol (150ml) was hydrogenated (p=3 bar) for 90 minutes with palladium-on-charcoal 10% (3.3 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off over celite, washed with CH₃OH and the solvent was evaporated. The residue (2.72 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 92/8/1). Two pure fractions were collected and their solvents were evaporated. Each residue was crystallized from 2-butanone and diethyl ether. The precipitate was filtered off and dried, yielding 0.39 g (14.5%) of (±)-(A)-3,4-dimethoxy-N-[4-[1-(1H-imidazol-1-yl)-2-(methylamino)propyl]phenyl]benzeneacetamide (compound 400).

EXAMPLE B20

[0140] A mixture of (±)-3,4-dimethoxy-N-[4-(3-methyl-2-oxiranyl)phenyl]benzeneacetamide (0.0442 mol) and 1H-imidazole (0.221 mol) in DMF (116 ml) was stirred and refluxed for 6 hours. The mixture was poured out into water and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.3). The desired fraction was taken up in CH₂Cl₂, washed with a saturated NaCl solution, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 93/7/1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 1.53 g (9%) of (±)-(B)-3,4-dimethoxy-N-[4-[2-hydroxy-1-(1H-imidazol-1-yl)propyl]phenyl]benzeneacetamide monohydrate (compound 402).

EXAMPLE B21

[0141] A mixture of (±)-(A)-3-[4-[[(3,4-dimethoxyphenyl)acetyl]amino]phenyl]-3-(1H-imidazol-1-yl)-2-methylpropyl methanesulfonate (0.0011 mol) in NaOCH₃ (1 ml) and methanol (5 ml) was stirred at 80° C. for 3 hours. The mixture was poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue (0.56g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97.5/2.5/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.2 g (43%) of (±)-(A)-3,4-dimethoxy-N-[4-[1-(1H-imidazol-1-yl)-3-methoxy-2-methylpropyl]phenyl]benzene-acetamide (compound 404).

EXAMPLE B22

[0142] a) A mixture of compound (698) (0.0329 mol) in NaOH 3N (300ml) was stirred and refluxed for 2 hours. The mixture was cooled, poured into ice, neutralized with concentrated HCl and extracted with CH₂Cl₂. The organic layer was dried, filtered and the solvent evaporated, yielding 7.91g (88%) of (±)-4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenylthiourea (compound 699).

[0143] b) An alternative reaction procedure is the following: A solution of trifluoroacetic acid (0.0715 mol) in benzene (5ml) was added dropwise to a solution of 4-[1-(1H-imidazol-1-yl)-2-methylpropyl]benzenamine (0.0511 mol) and NaSCN (0.102 mol) in benzene (70 ml), the mixture was stirred at RT for 1 hour and stirred further at 60° C. for 24 hours. The mixture was cooled to 30° C., and extracted with CH₂Cl₂ and K₂CO₃ 10%. The organic layer was washed with water, dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 95/5/0.5 to 90/10/0.5) (35-70 μm) and purified further by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 92/8/0.5) (15-40 μm). The pure fractions were collected and evaporated. The residue was recrystallized from 2-propanone and (C₂H₅)₂O and filtered off. The product was taken up in CH₂Cl₂, CH₃OH and norit. The product was recrystallized from 2-propanone and (C₂H₅)₂O and filtered off, yielding 1.42 g (±)-4-[1-(1H-imidazol-1-yl)-2-methylpropyl]-phenylthiourea (10%) (compound 699).

EXAMPLE B23

[0144] A mixture of compound (206) (0.0104 mol), 2-pyridinamine (0.0104 mol) and N,N-dimethyl-4-pyridinamine (0.0052 mol) in 1,4-dioxane (100 ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was dissolved in CH₂Cl₂. The organic solution was washed with a 10% aqueous K₂CO₃ solution, with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 97/3/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone and DIPE. The precipitate was filtered off and dried, yielding 1.10 g (34.3%) (35 )-N-(2-pyridinyl)-N′-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]urea (compound 274).

EXAMPLE B24

[0145] n-Butyllithium 1.6M in hexane (101.5 ml) was added dropwise at −70° C. under N₂ flow to a mixture of 1-methyl-1H-imidazole (0.162 mol) in THF (244ml). The mixture was stirred at −70° C. for 30 minutes. Chlorotriethylsilane (0.162 mol) was added. The mixture was allowed to warm to RT. n-Butyllithium 1.6M in hexane (101.5 ml) was added dropwise at −70° C. The mixture was stirred at −70° C. for 1 hour and brought to −15° C. A mixture of intermediate (9) (0.065 mol) in THF (152 ml) was added dropwise at −70° C. The mixture was allowed to warm to RT, stirred overnight, then poured out into a saturated NH₄Cl solution and extracted with EtOAc. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄0H 96/4/0.5 and 80/20/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off and dried, yielding 1.5 g (±)-N-[4-[2-(dimethylamino)-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-propyl]phenyl]acetamide (compound 771).

EXAMPLE B25

[0146] Benzoylchloride (0.067 mol) was added to a solution of NH₄SCN (5.09 g) in 2-propanone (150 ml) and the mixture was stirred and refluxed for 20 minutes. A solution of 4-[1-(1H-imidazol-1-yl)-2-methylpropyl]benzenamine (0.0557 mol) in 2-propanone (150 ml) was added and the mixture was stirred and refluxed at 80° C. overnight. The mixture was cooled, filtered through celite and the filtrate was evaporated. The residue was taken up in CH₂Cl₂. The organic layer was dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1). The pure fractions were collected and evaporated. The residue was recrystallized from 2-propanone and DIPE, yielding (±)-N-benzoyl-N′-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]thiourea (compound 698).

EXAMPLE B26

[0147] A mixture of compound (689) (0.0309 mol) and iodomethane (0.062 mol) in acetonitrile (100 ml) was stirred at 50° C. for 2 hours. The solvent was evaporated, yielding 10.9g (91%) (±)-N-[4-[1-hydroxy-1-(3-pyridinium)methyl]phenyl]acetamide iodide (compound 770)

EXAMPLE B27

[0148] A mixture of 1-[2-ethyl-1-(4-isothiocyanatophenyl)butyl]-1H-imidazole (0.0123 mol) and 2-benzothiazolamine (0.0148 mol) in acetonitrile (80 ml) was stirred and refluxed for 12 hours. The solvent was evaporated and the residue was taken up in H₂O and CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ NH₄OH 97.5/2.5/0.1). The desired fractions were collected and the solvent was evaporated. The residue was purified again by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 85/15/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-butanone and DIPE. The precipitate was filtered off and dried, yielding 0.44 g (9%) (±)-N-(2-benzothiazolyl)-N′-[4-[1-(1H-imidazol-1-yl)-2-ethylbutyl]phenyl]-thiourea (compound 705).

EXAMPLE B28

[0149] A mixture of compound (651) (0.0136 mol) and phosphorous pentasulfide (0.0136 mol) in pyridine (200 ml) was stirred and heated at 120° C. for 12 hours. The solvent was evaporated, the residue was taken up in water, NH₄OH, CH₂Cl₂ and CH₃OH (10%), and the mixture was stirred at RT for 15 minutes. The organic layer was decanted off, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The desired fractions were collected and evaporated. The residue was recrystallized from 2-propanone and DIPE, filtered off and dried, yielding (22%) 1.15 g 4-chloro-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]benzenethane-thioamide (compound 764).

EXAMPLE B29

[0150] A solution of methyl N′-(3-fluorophenyl)-N-[4-[1 -(lH-imidazol- 1 -yl)-2-methylpropyl]-phenyl]carbamimidothioate (0.0094 mol) in NH₃/CH30H (60ml) was stirred and heated in autoclave at 40° C. for 3 days. The solvent was evaporated and the residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 94/6/0.2 to 90.10/0.5). The pure fractions were collected and evaporated. The residue was crystallized from 2-propanone and (C₂H₅)₂O and filtered off, yielding 0.89 g (46%) N′-(3-fluorophenyl)-N-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]guanidine (compound 744).

EXAMPLE B30

[0151] A solution of KOCN (2.25 g) in water was added dropwise at RT to a mixture of 4-[1-(1H-imidazol-1-yl)-2-methylpropyl]benzenamine (0.0278 mol) in acetic acid (4ml) and water (50 ml) and the mixture was stirred at RT for 1 hour. The mixture was neutralized with NaOH 3N and extracted with CH₂Cl₂ and CH₃OH. The organic layer was washed with water, dried, filtered and the solvent evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.3). The pure fractions were collected and evaporated. The residue was recrystallized from 2-propanone, yielding 2.7 g (51.4%) (±)-4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenylurea (compound 266).

EXAMPLE B31

[0152] 4-Fluorophenylisocyanate (0.017 mol) was added to a solution of 4-[1-(lH-imidazol-1-yl)-2-methylpropyl ]benzenamine (0.014 mol) in dry THF (100 ml) and the mixture was stirred and refluxed for 2 hours. The mixture was cooled, the precipitate was filtered off and recrystallized from 2-propanone and CH₃OH, yielding 1.6g (32%) (±)-N-(4-fluorophenyl)-N′-[4-[1-(1H-imidazol-1-yl)-2-methylpropyl]phenyl]urea (compound 740).

EXAMPLE B32

[0153] CH₃I (0.00814 mol) was added at RT to a mixture of compound 792 (0.00814 mol) in 2-propanone (30ml). The mixture was stirred at RT for 6 hours, poured out into H₂O and a concentrated NH₄OH solution and extracted with CH₂Cl₂. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 3.18 g of methyl [4-[(2,5-dichlorophenyl)( lH-imidazol- 1 -yl)methyl]phenyl]carbamimidothioate (comp. 796).

EXAMPLE B33

[0154] Formamide (130ml) was added to a mixture of intermediate 15 (0.043 mol) in acetic acid (130 ml). The mixture was stirred at 150° C. for 2 hours, cooled, poured out into ice water and basified with a concentrated NH₄OH solution. The precipitate was filtered off, washed with H₂O and taken up in CH₂Cl₂ and a small amount of CH₃OH. The organic solution was dried, filtered and the solvent was evaporated. This fraction was crystallized from CH₂Cl₂, CH₃OH and DIPE. The precipitate was filtered off and dried, yielding 2.2 g (15.1%) of (±)-N-[4-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-phenyl]formamide (comp. 793).

EXAMPLE B34

[0155] Compound (779) (0.0132 mol) was separated into its enantiomers by column chromatography over silica gel (eluent: hexane/C₂H₅OH 80/20; column: CHIRACEL OD 20 μm). Two pure fractions were collected and their solvents were evaporated. The residue was dissolved in 2-propanone and 2-propanol and converted into the oxalic acid salt (1:1). The precipitate was filtered off and dried, yielding 2.55g of (A)-N-[4-[2-ethyl-1-(1H-imidazol-1-yl)butyl]phenyl]-3-hydroxybenzeneacetamide ethanedioate (1:1) (comp. 780) and 2.95g of (B)-N-[4-[2-ethyl-1-(1H-imidazol-1-yl)butyl]phenyl]-3-hydroxy-benzeneacetamide ethanedioate (1:1) (comp. 781).

[0156] Tables 1 to 20 list the compounds of formula (I) which were prepared analogous to one of the above examples. TABLE 1

Co. No X; R⁴; stereochemical descriptor if Co. No X; R⁴; stereochemical descriptor if (Ex No) not racemic and/or addition salt (Ex No) not racemic and/or addition salt  1 (B1) N; CH₃ 33 (B2) CH; 3,4-dihydro-2H-1- benzopyran-3-yl  2 (B2) N; C(CH₃)═CHC₆H₅; (E) 34 (B2) CH; 1,3-benzodioxolan-2-yl  3 (B2) N; C₆H₅ 35 (B2) CH; 4—OC₂H₅—C₆H₄  4 (B3) N; CH(OH)(4-Cl-C₆H₄) 36 (B2) CH; (2,3-dihydro-1,4- benzodioxin-6-yl)-CH₂  5 (B2) N; (1,3-benzodioxolan-5-yl)methyl 38 (B2) CH; (5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphtalenyl)-CH₂  6 (B2) N; (3,4-diOCH₃)C₆H₃ 39 (B2) CH; (CH₂)₂(4-OC₂H₅—C₆H₄)  7 (B2) N; (2,3-dihydro-1,4-benzodioxin-6- 40 (B5) CH; H yl)methyl  8 (B3) N; (CH₂)₃(3,4-diOCH₃—C₆H₃) 41(B2) CH; CH₂—(4-C₆H₅—C₆H₄)  9 (B2) N; OC₆H₅ 42 (B2) CH; CH₂Cl 10 (B3) N; (CH₂)₂(3,4-diOCH₃—C₆H₃) 43 (B9) CH; (1-piperidinyl)methyl 11 (B3) N; CH(OH)(3,4-diCH₃—C₆H₃) 44 (B9) CH; (4-CH₃-1-piperazinyl)-CH₂ 12 (B2) N; CH₂O(2-OCH₃—C₆H₄) 45 (B3) CH; 2-methoxy-5-pyridinyl 13 (B3) N; (2-NH₂-benzothiazol-6-yl)-CH₂ 46 (B3) CH; 1-(C₆H₅—CO)-4-piperidinyl 14 (B2) N; CH₂Cl 47 (B9) CH; (4-morpholinyl)-CH₂ 15 (B9) N; (4-CH₃-1-piperazinyl)-CH₂ 48 (B3) CH; (CH₂)₃(4-OC₂H₅—C₆H₄) 16 (B3) N; CH(OH)(4-Cl—C₆H₄); (A) 49 (B3) CH; CH₂O(2-OH-C₆H₄) 17 (B10) N; CH(OH)(4-Cl-C₆H₄); (A, A) 50 (B2) CH; CH(SCH₃)(C₆H₅) 18 (B10) N; CH(OH)(4-Cl—C₆H₄); (A, B) 51 (B3) CH; (2-OCH₃-5-pyridinyl)-CH₂ 19 (B3) N; CH(OH)(4-Cl—C₆H₄); (B) 52 (B3) CH; (CH₂)₃(3,4-diOCH₃—C₆H₃) 20 (B10) N; CH(OH)(4-Cl—C₆H₄); (B, A) 53 (B3) CH; 1-(tert-butoxy-carbonyl)-4- piperdinyl 21 (B10) N; CH(OH)(4-Cl—C₆H₄); (B, B) 54 (B3) CH; CH(OH)(4-Cl-C₆H₄) 22 (B2) CH; phenyl 55 (B3) CH; CH₂N(CH₃)₂ 23 (B2) CH; 2,3-dihydro-1,4-benzodioxin- 56 (B3) CH; CH(OH)(3,4-diOCH₃—C₆H₃) 2-yl 24 (B3) CH; C(OH)(CH₃)₂ 57 (B11) CH; 4-piperidinyl 25 (B2) CH; 1,4-benzodioxin-2-yl 58 (B3) H; (2-NH₂-6-benzothiazolyl)-CH₂ 26 (B2) CH; (2,3-dihydro-l,4-benzodioxin- 59 (B3) CH; 1-methyl-4-piperidinyl 2-yl)-CH₂ 27 (B2) CH; 2-pyrazinyl 60 (B2) CH; OC₆H₅ 28 (B2) CH; (1,3-benzodioxolan-5-yl)-CH₂ 61 (B10) CH; (CH₂)₂(4-OC₂H₅—C₆H₄); (A) 29 (B2) CH; 3,4-dihydro-2H-1-benzopyran- 62 (B10) CH; (CH₂)₂(4-OC₂H₅—C₆H₄); (B) 2-yl 30 (B2) CH; 5,5,8,8-tetramethyl-5,6,7,8- 63 (B23) N; 2-benzothiazolyl-NH— tetrahydro-2-naphtalenyl 31 (B2) CH; 2H-1-benzopyran-3-yl 64 (B23) CH; 2-benzothiazolyl-NH— 32 (B2) CH; (CH₂)₂(3,4-diOCH₃—C₆H₃) 777 (B3) N; 2-benzothiazolyl 37 (B2) CH; CH₂O(2-OCH₃—C₆H₄) 778 (B3) CH; 2-benzothiazolyl; oxalic acid (1:1)

[0157] TABLE 2

(R^(b))_(n); stereochemical (R^(b))_(n); stereochemical Co. Ex. descriptor if not racemic Co. Ex. descriptor if not racemic No. No. X and/or addition salt No. No. X and/or addition salt 65 B2 N 4-CH₃ 101 B2 CH 3-OC₂H₅; 4-OC₂H₅ 66 B2 N 4-Cl 102 B2 CH 2-OCH₃; 3-OCH₃ 67 B3 N 3-OH 103 B2 CH 4-OC₆H₅ 68 B2 N 4-F 104 B2 CH 2-CH₃ 69 B3 N 4-OH 105 B2 CH 4-OCH₃ 70 B2 N 3-OCH₃ 106 B2 CH 2-CH₃; 5-CH₃ 71 82 N 4-OC₂H₅ 107 B3 CH 2-OH 72 B3 N 3-OCH₃; 4-OH 108 B3 CH 3-OH; 4-OCH₃ 73 B2 N 3-OCH₃; 4-OCH₃ 109 B3 CH 3-OH; oxalic acid (1:1) 74 B2 N 3-Cl; 4-OCH₃ 110 B2 CH 3-O CH₃; 4-CH₃ 75 B2 N 3-Cl; 4-OC₂H₅ 111 B3 CH 4-OH 76 B2 N 3-CH₃; 4-OC₂H₅ 112 B2 CH 3-CH₃; 4-CH₃ 77 B2 N 3-CH₃; 4-CH₃ 113 B2 CH 2-OCH₃; 4-Cl 78 B3 N 3-CH₃; 4-OCH₃ 114 B2 CH 2-OCH₃; 6-OCH₃ 79 B3 N 3-Cl; 4-OH 115 B2 CH 2-OCH₂C₆H₅; 3-OCH₃ 80 B2 N 3-OCH₃; 4-OCH₃; 5-OCH₃ 116 B2 CH 3-Cl; 4-OCH₃ 81 B2 N 3-CH₃; 4-CH₃; 5-CH₃ 117 B3 CH 3-Cl; 4-OH 82 B3 N 3-OC₂H₅; 4-OC₂H₅ 118 B2 CH 3-Cl; 4-OC₂H₅ 83 B3 N 3-OCH₃; 4-Cl 119 B2 CH 3-OCH₃; 5-OCH₃ 84 B3 N 3-OCH₃; 4-CH₃ 120 B2 CH 2-OCH₂C₆H₅; 5-OCH₃ 85 B10 N 3-CH₃; 4-OCH₃; (A) 121 B3 CH 4-(2-pyridinylmethoxy) 86 B10 N 3-CH₃; 4-OCH₃; (B) 122 B2 CH 2-OCH₃; 5-CH₃ 87 B2 CH 4-Cl 123 B2 CH 3-CH₃; 4-OCH₃ 88 B2 CH 4-F 124 B3 CH 2-OH; 5-CH₃ 89 B2 CH 2-OCH₃ 125 B2 CH 3-CH₃; 4-OC₂H₅ 90 B2 CH 3-OCH₃ 126 B3 CH 2-OCH₃; 4-OCH₃ 91 B2 CH 3-OCH₃; 4-OCH₃ 127 B3 CH 4-(4-pyridinylmethoxy) 92 B2 CH 4-OCH(CH₃)₂ 128 B3 CH 3-OC₂H₅; 4-OCH₂C₆H₅ 93 B2 CH 4-O(CH₂)₂CH₃ 129 B3 CH 2-CH₃; 4-OH 94 B2 CH 4-CH₃ 130 B3 CH 4-(3-pyridinylmethoxy) 95 B2 CH 4-OC₂H₅ 779 B3 CH 3-OH 96 B2 CH 4-O(CH₂)₃CH₃ 780 B34 CH 3-OH; (A); oxalic acid (1:1) 97 B3 CH 3-OCH₃; 4-OH; 781 B34 CH 3-OH; (B); oxalic acid (1:1) oxalic acid (1:1) 98 B2 CH 2-OCH₃; 5-OCH₃ 782 B34 N 3-OCH3; 4-CH3; (A) 99 B3 CH 4-N(CH₃)₂ 783 B34 N 3-OCH3; 4-CH3; (B) 100  B2 CH 3-CH₃

[0158] TABLE 3

(R^(b))_(n); stereochemical (R^(b))_(n); stereochemical Co. Ex. descriptor if not racemic Co. Ex. descriptor if not racemic No. No. X and/or addition salt No. No. X and/or addition salt 131 B2 N 4-Cl 142 B3 CH 3-OCH₃; 4-OH 132 B2 N 4-F 143 B3 CH 3-Cl; 4-Cl 133 B2 N 4-CH₃ 144 B2 CH 4-NO₂; (A) 134 B3 N 4-OH 145 B7 CH 4-NH₂; (A) 135 B2 N 4-OC₂H₅ 146 B2 CH 4-NO₂; (B) 136 B2 N 3-OCH₃; 4-OCH₃; 147 B7 CH 4-NH₂; (B) hydrate (1:1) 137 B3 N 3-OH 148 B3 CH 3-I; 4-NH₂ 138 B3 N 3-OCH₃; 4-OH 149 B3 CH 3-I; 4-NH₂; (B) 139 B2 CH 3-OCH₃; 4-OCH₃; 5-OCH₃ 150 B3 CH 3-I; 4-NH₂; (A) 140 B2 CH 3-OCH₃; 4-OCH₃ 151 B2 CH 4-NO₂ 141 B3 CH 2-Cl; 4-Cl 152 B7 CH 4-NH₂

[0159] TABLE 4

Co No X; R⁴; stereochemical descriptor Co No X; R⁴; stereochemical descriptor if (Ex No) if not racemic and/or addition salt (Ex No) not racemic and/or addition salt 153 (B1) N; CH₃; 216 (B3) CH; 2-quinoxalinyl 154 (B2) N; C(CH₃)═CHC₆H₅; (E) 217 (B2) CH; 3,4-dihydro-2H-1-benzopyran- 2-yl 155 (B2) N; CH═CHC₆H₅; (E) 218 (B6a) CH; (CH₂)₃C(═O)OH 156 (B2) N; C(CH₃)═CH(3-Cl-C₆H₄); (E) 219 (B6b) CH; (CH₂)₃C(═O)OC₂H₅ 157 (B2) N; C(CH₃)═CH(4-F-C₆H₄); (E) 220 (B2) CH; 5-bromo-2-furanyl 158 (B2) N; C(CH₃)═CH(4-pyridinyl); (E) 221 (B2) CH; 3-F-C₆H₄ 159 (B2) N; C(CH₃)═CH(4-CF₃—C₆H₄); (E) 122 (B3) CH; C(CH₃)₂[O(4-Cl—C₆H₄)] 160 (B2) N; CF═CHC₆H₅; (Z) 223 (B3) CH; CH₂—S—C₆H₅ 161 (B2) N; 1,3-benzodioxolan-2-yl 224 (B3) CH; (2-pyrimidinylthio)methyl 162 (B2) N; (2,3-dihydro-1,4-benzodioxin- 225 (B3) CH; 5-methyl-2-pyrazinyl 2-yl)methyl 163 (B2) CH; C₂H₅ 226 (B2) CH; 3-methyl-2-furanyl 164 (B4) CH; CH(CH₃)—CH₂(C₆H₅) 227 (B3) CH; 4-quinolinyl 165 (B2) CH; CH(CH₃)—CH═CHC₆H₅; (E) 228 (B3) CH; 1,2-dihydro-2(1H)-pyridinone- 3-yl 166 (B2) CH; C₆H₅ 229 (B3) CH; 1-isoquinolinyl 167 (B2) CH; 2-benzofuranyl 230 (B2) CH; 2,3-dihydro-1,4-benzodioxin- 5-yl 168 (B2) CH; 2-benzothienyl 231 (B2) CH; 3,4-(OCH₃)₂—C₆H₃ 169 (B2) CH; 2-furanyl 232 (B2) CH; 1,3-benzodioxolan-5-yl 170 (B2) CH; 2-pyrazinyl 233 (B3) CH; 5-quinoxalinyl 171 (B2) CH; C(CH₃)═C(C₆H₅) 234 (B2) CH; 1,4-benzodioxin-2-yl (3-pyridinyl); (E + Z) 172 (B2) CH; 3-furanyl 235 (B2) CH; 2-furanylmethyl 173 (B2) CH; 3-thienyl 236 (B3) CH; C(OH)(CH₃)₂ 174 (B2) CH; 1-cyclohexenyl 237 (B2) CH; (2,3-dihydro-1,4-benzodioxin- 2-yl)methyl 175 (B2) CH; 2,3-dihydro-1,4-benzodioxin- 238 (B2) CH; 4-(C₆H₅)—C₆H₄ 2-yl 176 (B2) CH; C(CH₃)═C(C₆H₅)(CH₃); (E) 239 (B3) CH; (4-pyridinylthio)methyl 177 (B5) CH; H 240 (B3) CH; (2-naphtalenyl)methyl 178 (B2) CH; 2-indolyl 241 (B3) CH; 3-quinolinyl 179 (B2) CH; 2-naphtalenyl 242 (B3) CH; 3,5-dimethyl-4-isoxazolyl 180 (B2) CH; 1-methyl-2-indenyl 243 (B2) CH; 2,3-dihydro-1,4-benzoxathiin- 2-yl 181 (B2) CH; 2-oxolanyl 244 (B3) CH; 2-thienylmethyl 182 (B2) CH; 1-naphtalenyl 245 (B3) CH; 3-thienylmethyl 183 (B2) CH; OC₂H₅ 246 (B3) CH; 1-naphtalenylmethyl 184 (B2) CH; 1-methylbenzotriazol-6-yl 427 (B3) CH; 2-pyridinylmethyl 185 (B2) CH; 3-oxolanyl 248 (B2) CH; 1,3-benzodioxolan-2-yl 186 (B2) CH; 2-phenyl-4-thiazolyl 249 (B3) CH; CH(OH)—CH₃ 187 (B2) CH; 2-thienyl 250 (B3) CH; 5-methyl-3-phenyl-4-isoxazolyl 188 (B2) CH; (CH₂)₂CH₂Cl 251(B3) CH; 3-pyridinylmethyl 189 (B2) CH; C(CH₃)(C₆H₅)₂ 252 (B2) CH; 5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphtalenyl 190 (B2) CH; 1-C₆HPHD 5-cyclopropyl 253 (B2) CH; 3,4-dihydro-2H-1-benzopyran- 3-yl 191 (B2) CH; 1-C₆H_(5-cyclopentyl) 254 (B2) CH; 2H-1-benzopyran-3-yl 192 (B2) CH; cyclopentyl 255 (B2) CH;(2,3-dihydro-1,4-benzodioxin- 6-yl)methyl 193 (B2) CH; cyclohexyl 256 (B2) CH; (5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphtalenyl)methyl 194 (B3) CH; 4-pyridinyl 257 (B1) CH; CH₃; (A) 195 (B3) CH; 1-methyl-2-pyrrolyl 258 (B1) CH; CH₃; (B) 196 (B3) CH; 3-pyridinyl 259 (B8) CH; CH₂(3-iodo-4-azido-C₆H₃); (B) 197 (B2) CH; 2-methylcyclopropyl 260 (B8) CH; CH₂(3-iodo-4-azido-C₆H₃); (A) 198 (B3) CH; C C(C₆H₅) 261 (B3) CH; CH₂13 NH—C(═O)—C₆H₅ 199 (B3) CH; cyclopropyl 262 (B3) CH; CH₂—NH—C(═O)—O—CH₂—C₆H₅ 200 (B2) CH; 1-C₆H₅-cyclohexyl 263 (B23) CH; N(CH₃)—CH₂—C₆H₅ 201 (B2) CH; 1-methylcyclohexyl 264 (B6a) CH; CH₂-[1-(CH₂COOH)cyclopentyl] 202 (B2) CH; 2-methylcyclohexyl 265(B6a) CH; (CH₂)₂—C(═O)—OH 203 (B3) CH; C(CH₃)═C(C₆H₅)—C₂H₅; (Z) 266 (B30) CH; NH₂ 204 (B2) CH; 2-phenylcyclopropyl; 267 (B23) CH; NH—CH₃ oxalic acid (1:1) 205 (B2) CH; 3,4-dihydro-2(1H)- 268 (B3) CH; NH—C(CH₃)₂ quinolinone-6-yl 206 (B2) CH; OC₆H₅ 269 (B3) CH; NH—CH₂—C₆H₅ 207 (B3) CH; C(CH₃)═C(C₆H₅)(2- 270 (B3) CH; NH-(3-pyridinyl) furanyl); (F) 208 (B3) CH; 2-pyridinyl 271 (B23) CH; NH-(2-pyrazinyl) 209 (B2) CH; CH(CH₃)CH₃ 272 (B31) CH; NH-(1-naphtalenyl) 210 (B3) CH; CH₂—S—CH₂C₆H₅ 273 (B23) CH; NH—CH₂-(4-Cl-C₆H₄) 211 (B3) CH; CH₂—OC₆H₅ 274 (B23) CH; NH-(2-pyridinyl) 212 (B3) CH; CH₂—OCH₃ 275 (B23) CH; NH-(4-pyridinyl) 213 (B3) CH; CH₂—NH—C₆H₅ 276 (B23) CH; NH-(6-benzodioxanyl) 214 (B3) CH; 6-quinoxalinyl 277 (B23) CH; NH-(1-CH₃-2-benzimidazolyl) 215 (B3) CH; 2-quinolinyl

[0160] TABLE 5

(R^(b))_(n); stereochemical (R^(b))_(n); stereochemical Co. Ex. descriptor if not racemic Co. Ex. descriptor if not racemic No. No. X and/or addition salt No. No. X and/or addition salt 278 B2 N 3-OCH₃; 4-OCH₃; (A) 301 B3 CH 3-OC₂H₅; 4-OC₂H₅; (B) 279 B3 N 3-Cl; 4-OCH₃; (A) 302 B3 CH 3,4,5-(OCH₃)₃; (A) 280 B3 N 3-CH₃; 4-CH₃; (B) 303 B3 CH 3-Cl; 4-OH; (A) 281 B3 N 4-OCH₃; 3-CH₃; (B) 304 B2 CH 3-Cl; 4-OCH₃; (A) 282 B3 N 3-CH₃; 4-CH₃; (A) 305 B3 CH 3-Cl; 4-OCH₃; (B) 283 B3 N 4-Cl; (B) 306 B3 CH 3-CH₃; 4-CH₃; (B) 284 B3 N 3-Cl; 4-OH; (A) 307 B3 CH 3-Cl; 4-OH; (B) 285 B3 N 3-OC₂H₅; 4-OC₂H₅; (A) 308 B3 CH 3-CH₃; 4-CH₃; 5-CH₃; (A) 286 B3 N 3-CH₃; 4-OCH₃; (A) 309 B3 CH 3-CH₃; 4-CH₃; 5-CH₃; (B) 287 B3 N 3-OCH₃; 4-OCH₃; (B) 310 B3 CH 3-OCH₃; 4-Cl; (A) 288 B3 N 3-Cl; 4-OCH₃; (B) 311 B3 CH 3-OCH₃; 4-Cl; (B) 289 B3 N 3-Cl; 4-OH; (B) 312 B3 CH 3-CH₃; 4-OCH₃; (A) 290 B3 N 3-CH₃; 4-CH₃; 5-CH₃; (A) 313 B3 CH 3-CH₃; 4-OCH₃; (B) 291 B3 N 3-CH₃; 4-CH₃; 5-CH₃; (B) 314 B3 CH 3-OCH₃; 4-CH₃; (A) 292 B3 N 3,4,5-(OCH₃)₃; (B) 315 B3 CH 3-OCH₃; 4-CH₃; (B) 293 B3 N 3-OC₂H₅; 4-OC₂H₅; (B) 316 B3 CH 4-OCH(CH₃)₂; (B) 294 B3 N 3-OCH₃; 4-CH₃; (A) 317 B3 CH 4-N(CH₃)₂; (A) 295 B3 N 3-OCH₃; 4-CH₃; (B) 318 B3 CH 3-OCH₃; 4-OCH₃; (A) 296 B3 N 3-OCH₃; 4-Cl; (A) 319 B3 CH 4-O(CH₂)₃CH₃; (A) 297 B3 N 3-OCH₃; 4-Cl; (B) 320 B3 CH 4-O(CH₂)₃CH₃; (B) 298 B10 N 3-Cl; 4-OH; (A, A) 321 B3 CH 4-OCH(CH₃)₂; (A) 299 B10 N 3-Cl; 4-OH; (A, B) 784 B34 N 4-Cl; (B, A) 300 B3 CH 3-OC₂H₅; 4-OC₂H₅; (A) 785 B34 N 4-Cl; (B, B)

[0161] TABLE 6

Co No X; R⁴; stereochemical descriptor Co No X; R⁴; stereochemical descriptor if (Ex No) if not racemic and/or addition salt (Ex No) not racemic and/or addition salt 322 (B3) N; (2,3-dihydro-1,4-benzodioxin- 339 (B3) CH; (2,3-dihydro-1,4-benzodioxin- 6-yl)methyl; (A) 6-yl)methyl; (B) 323 (B2) N; OC₆H₅; (A) 340 (B2) CH; (1,3-benzodioxolan-5-yl) methyl; (A) 324 (B2) N; 3,4-diOCH₃—C₆H₃; (A) 341 (B3) CH; 3,4-diOCH₃—C₆H₃; (A) 325 (B2) N; (1,3-benzodioxolan-5-yl)- 342 (B3) CH; 3,4-diOCH₃—C₆H₃; (B) methyl; (A) 326 (B3) N; (CH₂)₃(3,4-diOCH₃—C₆H₃); (A) 343 (B2) CH; OC₆H₅; (A) 327 (B3) N; 3,4-diOCH₃—C₆H₃; (B) 344 (B2) CH; OC₆H₅ 328 (B3) N; (CH₂)₂(3,4-diOCH₃—C₆H₃); (B) 345 (B5) CH; H; (A) 329 (B3) N; (CH₂)₃(3,4-diOCH₃—C₆H₃); (B) 346 (B3) CH; (CH₂)₂(4-OC₂H₅—C₆H₄); (A) 330 (B3) N; (1,3-benzodioxolan-5- 347 (B9) CH; 4-methylpiperazinyl; (A) yl)methyl;(B) 331 (B5) N; H; (B) 348 (B3) CH; (CH₂)₂(4-OC₂H₅—C₆H₄) 332 (B3) N; C(CH₃)═CH(C₆H₅); [B-(E)] 349 (B9) CH; 4-methylpiperazinyl; (B) 333 (B3) N; (2,3-dihydro-1,4-benzodioxin- 350 (B3) CH; CH[O(2-OCH₃—C₆H₄)]; (A) 6-yl)methyl; (B) 334 (B2) N; OC₆H₅; (B) 351 (B3) CH; CH[O(2-OCH₃—C₆H₄)]; (B) 335 (B5) N, H; (A) 352 (B3) CH; (4-CH₃-piperazinyl)methyl; (A) 336 (B3) CH; (CH₂)₃(3,4-diOCH₃—C₆H₃); (B) 353 (B3) CH; (4-CH₃-piperazinyl)methyl; (B) 337 (B3) CH; (1,3-benzodioxolan-5-yl)- 354 (B3) CH; (4-CH₃-piperazinyl)ethyl methyl; (B) 338 (B3) CH; (2,3-dihydro-1,4-benzodioxin- 6-yl)methyl; (A)

[0162] TABLE 7

Co No R¹; stereochemical descriptor if Co No R¹; stereochemical descriptor if not (Ex No) not racemic and/or addition salt (Ex No) racemic and/or addition salt 355 (B2) (CH₂)₂CH(CH₃)₂ 367 (B2) CH[N(CH₃)₂]CH₃; (A) 356 (B3) 4-Cl—C₆H₄ 368 (B2) CH[N(CH₃)₂]CH₃; (B) 357 (B2) C₆H₅ 369 (B2) CH(S—C₆H₅)CH₃; (B) 358 (B2) CH₃ 370 (B2) CH(O—C₆H₅)CH₃; (A) 359 (B2) CH₂CH(CH₃)₂ 371 (B2) CH(CH₃)CH₂CN; (A + B) 360 (B2) CH₂-—(CH₃)₃ 372 (B2) C₂H₅ 361 (B2) 3-CF₃—C₆H₄ 373 (B2) 5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphtalenyl 362 (B2) cyclohexyl 374 (B2) CH(CH₃)C₃H₇; (B) 363 (B2) (CH₂)₂CH₃ 375 (B2) CH₂[N(CH₃)₂] 364 (B2) CH(CH₃)CH₂CH₃ 376 (B2) CH(S—C₆H₅)CH₃; (A) 365 (B2) C(CH₃)₃ 377 (B2) CH(CH₃)CH₂C₆H₅ 366 (B3) 1-(1-piperidinyl)ethyl; (A)

[0163] TABLE 8

Co No R¹; stereochemical descriptor if Co No R¹; stereochemical descriptor if not (Ex No) not racemic and/or addition salt (Ex No) racemic and/or addition salt 378 (B2) CH(C₃H₇)₂ 399 (B3) CH[N(CH₃)(CH₂C₆H₅)]CH₃ 379 (B3) CH(CH₃)[N(CH₃)2]; (B) 400 (B19) CH[NH(CH₃)]CH₃; (A) 380 (B3) CH₂[N(CH₃)₂] 401 (B19) CH[NH(CH₃)]CH₃; (B); hydrate (1:1) 381 (B3) CH[C(═O)OC₂H₅]CH₃; (A) 402 (B20) CH(OH)CH₃; (B); hydrate (1:1) 382 (B3) CH[C(═O)OC₂H₅]CH₃; (B) 403 (B18) (CH₂)₂(OH) 383 (B3) CH[N(C₂H₅)₂]CH₃; (B) 404 (B21) CH(CH₃)CH₂OCH₃; (A) 384 (B3) CH(CH₃)C₅H₁₁; (A) 405 (B21) CH(CH₃)CH₂OCH₃; (B) 385 (B3) CH(CH₃)C₅H₁₁; (B) 406 (B3) CH[N(CH₃)(C₄H₉)]CH₃; (A) 386 (B18) CH(CH₃)CH₂OH; (A) 407 (B3) CH[N(CH₃)[(CH₂)₂N(CH₃)₂]]CH₃; (A) 387 (B3) CH[N(C₂H₅)₂]CH₃; (A) 408 (B3) 1-(4-morpholinyl)ethyl; (A) 388 (B3) CH[N(CH₃)₂]C₂H₅; (B) 409 (B3) 1-(4-morpholinyl)ethyl; (B) 389 (B3) [1-CH₃-2-(1-piperidinyl)]C₂H₅; (B) 410 (B3) 1-methyl-3-piperidinyl; (A) 390 (B3) [1-CH₃-2-(1-piperidinyl)]C₂H₅; (A) 411 (B3) 1-methyl-2-piperidinyl; (A) 391 (B3) CH(CH₃)[CH₂[N(CH₃)₂]]; (B) 412 (B3) l-(4-methyl-1-piperazinyl)ethyl; (A); hydrate (1:1) 392 (B3) CH(CH₃)[CH₂[N(CH₃)₂]]; (A) 413 (B3) CH[N(CH₃)(C₃H₇)]CH₃; (A) 393 (B3) [1-N(CH₃)₂]C₃H₇; (A) 414 (B3) CH[N(CH₃)(C₃H₇)]CH₃; (B) 394 (B18) (1-CH₃)C₂H₅OH; (B) 415 (B3) CH[N(CH₃)[(CH₂)₂C₆H₅]]CH₃ 395 (B3) CH₂C(═O)OC₂H₅ 416 (B3) CH[N(CH₃)(C₂H₅)]CH₃; (A) 396 (B3) CH[N(CH₃)(CH₂C₆H₅)]CH₃; (B) 417 (B3) CH[OC(═O)N(CH₂C₆H₅)₂]CH₃; (A) 397 (B17) CH₂OCH₃ 418 (B3) CH[N(CH₂C₆H₅)₂]CH₃; (B) 398 (B3) CH[N(CH₃)(CH₂C₆H₅)]CH₃; (A) 419 (B3) CH[N(CH₂C₆H₅)₂]CH₃; (A)

[0164] TABLE 9

Co. Ex. R⁴; stereochemical descriptor if not No. No. X R¹ R³ racemic and/or addition salt 420 B3 CH C₆H₅ H CH(OH)C₆H₅ 421 B2 CH CH(CH₃)₂ CH₃ C(CH₃)═CHC₆H₅; (E) 422 B2 CH CH(CH₃)₂ C₂H₅ C(CH₃)═CHC₆H₅; (E) 423 B3 CH 4-Cl—C₆H₄ H CH(OH)C₆H₅ 424 B2 CH C₆H₅ H 2-pyrazinyl 425 B2 CH C₆H₅ H 2,3-dihydro-1,4-benzodioxin-2-yl 426 B2 CH C₆H₅ H (2,3-dihydro-1,4-benzodioxin-2-yl)- methyl 427 B2 CH CH(C₂H₅)₂ CH₃ CH₂(3,4-diOCH₃—C₆H₃) 428 B3 CH CH[N(CH₃)₂]CH₃ H CH₂(3,4,5-triOCH₃—C₆H₂); (B) 429 B3 CH CH[N(CH₃)₂]CH₃ H (CH₂)₂(3,4-diOCH₃—C₆H₃); (B) 430 B3 CH CH[N(CH₃)₂]CH₃ H (CH₂)₂(3,4-diOCH₃—C₆H₃); (A) 431 B3 CH CH[N(CH₃)₂]CH₃ H (CH₂)₃(3,4-diOCH₃—C₆H₃); (A); oxalic acid (1:1) 432 B3 CH 2-butyl H CH₂(3-OCH₃-4-OH-C₆H₃) 433 B3 CH CH₂[N(CH₃)₂] H CH₂(3,4-diCH₃—C₆H₃) 434 B3 CH CH₂[N(CH₃)₂] H 3,4-diOCH₃—C₆H₃ 435 B2 CH CH₂[N(CH₃)₂] H OC₆H₅ 436 B9 CH CH₂[N(CH₃)₂] H 4-methyl-1-piperazinyl 437 B2 N CH(CH₃)[N(CH₃)₂] CH₃ CH₂(3,4-diOCH₃—C₆H₃); (B) 438 B2 N CH(CH₃)[N(CH₃)₂] CH₃ CH₂(3,4-diOCH₃—C₆H₃); (A) 439 B2 CH CH(CH₃)[N(CH₃)₂] CH₃ CH₂(3,4-diOCH₃—C₆H₃); (A)

[0165] TABLE 10

Co No R¹; R⁶; stereochemical descriptor Co No R¹; R⁶; stereochemical descriptor if (Ex No) if not racemic and/or addition salt (Ex No) not racemic and/or addition salt 440 (B2) 4-Cl—C₆H₄; H 472 (B3) CH(CH₃)₂; cyclopentyl; (E) 441 (B2) 3-Cl—C₆H₄; H 473 (B3) CH(CH₃)₂; cyclohexyl; (E) 442 (B2) 3-F—C₆H₄; H 474 (B2) CH₂CH(CH₃)₂; CH₃; (E) 443 (B2) 4-F—C₆H₄; H 475 (B2) (CH₂)₂CH(CH₃)₂; CH₃; (E) 444 (B2) C₆H₅; C₆H₅ 476 (B2) CH₂C(CH₃)₃; CH₃; (E); hydrate (2:1) 445 (B2) C₆H₅; CH₃ 477 (B2) 1,3-dioxan-5-yl; CH₃; (E) 446 (B2) 4-F—C₆H₄; CH₃ 478 (B2) CH(C₂H₅)₂; CH₃; (B) 447 (B2) 4-Cl—C₆H₄; C₆H₅ 479 (B2) CH═CH—CH(CH₃)₂; CH₃; (E, E) 448 (B2) 3-Cl—C₆H₄; CH₃ 480 (B2) CH(CH₃)C₂H₅; CH₃; (E) 449 (B2) 3-Cl—C₆H₄; C₆H₅ 481 (B2) C(CH₃)₃; CH₃; (E) 450 (B2) 4-F—C₆H₄; C₆H₅ 482 (B2) CH(CH₃)C₃H₇; CH₃; [A-(E)] 451 (B2) 4-Cl—C₆H₄; CH₃ 483 (B2) CH(S—C₆H₅)CH₃; CH₃; (A) 452 (B2) C₆H₅; C₂H₅ 484 (B2) CH(S—C₆H₅)CH₃; CH₃; (B) 453 (B2) C₆H₅; C₃H₇ 485 (B2) CH(C₆H₅)₂; CH₃; (E) 454 (B2) CH(CH₃)₂; C₆H₅ 486 (B2) CH(C₃H₇)₂; CH₃; (E) 455 (B2) CH(CH₃)₂; CH₃; (B) 487 (B2) CH(CH₃)C₅H₁₁; CH₃; [A-(E)] 456 (B2) CH(CH₃)₂; 2-CH₃—C₆H₄ 488 (B2) CH(CH₃)C₅H₁₁; CH_(3; [B-(E]) 457 (B2) CH(CH₃)₂; C₂H₅ 489 (B2) CH(C₆H₅)CH₃; CH₃; [A-(E)] 458 (B10) CH(CH₃)₂; CH₃; (+)-[A-(E)] 490 (B2) CH(C₆H₅)CH₃; CH₃; [B-(E)] 459 (B10) CH(CH₃)₂; CH₃; (−)-[B-(E)] 491 (B2) 5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphtalenyl; CH₃; (E) 460 (B2) C₂H₅; CH₃; (E) 492 (B2) CH(C₂H₅)C₅H₁₁; CH₃; [A-(E)] 461 (B2) CH(CH₃)₂; F; (E) 493 (B2) CH(C₂H₅)C₄H₉; CH₃; (E) 462 (B2) C₄H₉; CH₃; (E) 494 (B2) CH(C₂H₅)C₅H₁₁; CH₃; [B-(E)] 463 (B2) cyclohexyl; CH₃; (E) 495 (B2) CH[N(CH₃)₂]CH₃; CH₃; [A-(E)] 464 (B2) CH(CH₃)₂; C₃H₇; (E) 496 (B3) CH[N(CH₃)₂]CH₃; CH₃; [B-(E)] 465 (B2) CH(CH₃)₂; C₄H₉; (E) 497 (B2) C₆H₅; H 466 (B2) CH₃; CH₃; (E) 498 (B2) H; H 467 (B2) C₃H₇; CH₃; (E) 499 (B2) CH(CH₃)₂; H 468 (B2) cyclohexyl; C₆H₅; (E) 500 (B2) 4-Br—C₆H₄; H 469 (B2) cyclopropyl; CH₃; (E) 501 (B2) 4-CH₃—C₆H₄; H 470 (B2) cyclopentyl; CH₃; (E) 502 (B2) CH(CH₃)₂; H; (E) 471 (B3) CH(CH₃)₂; CH(CH₃)₂; (E) 786 (B3) 2,5-diCl—C₆H₃; CH₃; (E)

[0166] TABLE 11

R¹; R⁶; R⁷; stereochemical Co No descriptor if not racemic and/or (Ex No) addition salt 503 (B2) C₆H₅; H; C₆H₅ 504 (B2) 4-Cl—C₆H₄; H; C₆H₅ 505 (B2) 3-Cl—C₆H₄; H; C₆H₅ 506 (B2) 4-F—C₆H₄; H; C₆H₅ 507 (B2) 4-Cl—C₆H₄; H; C₂H₅ 508 (B2) 4-F—C₆H₄; H; CH₃ 509 (B2) H; H; C₆H₅ 510 (B2) CH₃; H; C₆H₅ 511 (B2) CH(CH₃)₂; H; C₆H₅ 512 (B2) 4-Cl—C₆H₄; H; CH₃ 513 (B3) 4-Cl—C₆H₄; H; C₄H₉ 514 (B3) 4-Cl—C₆H₄; H; cyclohexyl; (E + Z) 515 (B3) 4-Cl—C₆H₄; H; CH(CH₃)₂; (E + Z) 516 (B2) 4-Cl—C₆H₄; H; 3-pyridinyl 517 (B2) 4-F—C₆H₄; H; 3-pyridinyl 518 (B3) CH(CH₃)₂; CH₃; 3-thienyl; (E + Z) 519 (B3) CH(CH₃)₂; CH₃; C₃H₇; (E + Z) 520 (B3) 4-Cl—C₆H₄; H; 3,5-diCl—C₆H₃

[0167] TABLE 12

Co No R¹; stereochemical descriptor if (Ex No) not racemic and/or addition salt 521 (B17) CH(CH₃)₂ 522 (B1) 3-Cl—C₆H₄ 523 (B1) 3-F—C₆H₄ 524 (B1) 3-CF₃—C₆H₄ 525 (B1) cyclohexyl 526 (B17) cyclopropyl 527 (B17) cyclopentyl 528 (B17) (CH₂)₂CH(CH₃)₂ 529 (B17) CH₂C(CH₃)₃ 530 (B17) 1,3-dioxan-5-yl 531 (B1) CH(C₂H₅)₂ 532 (B17) CH═CH—CH(CH₃)₂ 533 (B1) CH(CH₃)C₂H₅ 534 (B1) C(CH₃)₃ 535 (B1) CH[N(CH₃)₂]CH₃; hydrate (1:1) 536 (B1) CH(CH₃)(n-C₃H₇) 537 (B1) 1-(1-piperidinyl)ethyl 538 (B1) CH(S—C₆H₅)CH₃; (A + B) 539 (B1) CH(O—C₆H₅)CH₃ 540 (B1) CH(CH₃)CH₂CN 541 (B1) CH(C₆H₅)₂ 542 (B1) CH(C₂H₅)(n-C₃H₇) 543 (B1) CH(n-C₃H₇)₂ 544 (B17) CH(C₆H₅)CH₃ 545 (B17) 5,5,8,8-tetramethyl-5,6,7,8-tetra- hydro-2-naphtalenyl 546 (B17) CH(CH₃)(n-C₅H₁₁) 547 (B17) CH(C₂H₅)(n-C₅H₁₁) 548 (B1) CH₂N(CH₃)₂ 549 (B1) CH(C₂H₅)(n-C₄H₉) 550 (B17) 1-(ethoxycarbonyl)ethyl 551 (B1) CH[N(CH₃)₂]CH₃; (A); hydrate (1:1) 552 (B1) CH[N(CH₃)₂]CH₃; (B) 553 (B1) CH(CH₃)[CH₂(C₆H₅)] 554 (B1) CH[N(C₂H₅)₂]CH₃; (A) 555 (B1) CH[N(C₂H₅)₂]CH₃; (B) 556 (B1) CH[N(C₂H₅)₂]CH₃ 557 (B1) CH[N(CH₃)₂]C₂H₅; (A) 558 (B1) CH[N(CH₃)₂]C₂H₅; (B) 559 (B1) CH[N(CH₃)₂]C₂H₅ 560 (B1) (ethoxycarbonyl)methyl 561 (B17) CH[N(CH₃)(CH₂—C₆H₅)]CH₃ 562 (B1) CH[N(CH₃)(n-C₄H₉)]CH₃ 563 (B1) CH[N(CH₃)[(CH₂)₂N(CH₃)₂]]CH₃ 564 (B17) 1-(4-morpholinyl)ethyl 565 (B1) CH[N(CH₃)₂]C₂H₅ 566 (B1) CH[N(CH₃)(C₂H₅)]CH₃ 567 (B1) 1-methyl-3-piperidinyl 568 (B1) 1-methyl-2-piperidinyl; (A) 569 (B1) 1-(4-methyl-1-piperazinyl)ethyl 570 (B1) CH[N(CH₃)(n-C₃H₇)]CH₃ 571 (B1) CH[N(CH₃)(C₂H₅—C₆H₅)]CH₃ 572 (B1) CH[N(CH₂—C₆H₅)₂]CH₃ 573 (B1) CH[OC(═O)N(CH₂—C₆H₅)₂]CH₃ 787 (B17) 2,5-diCl—C₆H₃

[0168] TABLE 13

Co No R⁷; stereochemical descriptor if (Ex No) not racemic and/or addition salt 574 (B2) CH₃; (E) 575 (B3) 3-pyridinyl; (E) 576 (B3) 4-pyridinyl; (E) 577 (B2) 3-Cl—C₆H₄; (E) 578 (B2) 3-CF₃—C₆H₄ 579 (B2) 4-Cl—C₆H₄; (E) 580 (B2) 4-CF₃—C₆H₄; (E) 581 (B2) cyclohexyl; (E) 582 (B2) 4-OCH₃—C₆H₄; (E) 583 (B2) 4-F—C₆H₄; (E) 584 (B2) 3-OCH₃—C₆H₄; (E) 585 (B2) 2-F—C₆H₄; (E) 586 (B2) 3-F—C₆H₄; (E) 587 (B2) (CH₂)₂C₆H₅; (E) 588 (B2) CH(CH₃)₂; (E) 589 (B2) CH₂C₆H₅; (E) 590 (B2) 6-quinolinyl; (E) 591 (B2) 2-naphtalenyl; (E) 592 (B2) 4-quinolinyl; (E); hydrate (2:1) 593 (B2) 1-naphtalenyl; (E) 594 (B2) 2-furanyl; (E) 595 (B2) 2-thienyl; (E) 596 (B2) 3-thienyl; (E) 597 (B3) H 598 (B2) 2(1H)-quinolinone-6-yl; (E); hydrate (2:1) 599 (B2) 2-methyl-2H-benzotriazole-5-yl; (E) 600 (B2) 2-benzofuranyl; (E) 601 (B2) 5-methyl-2-furanyl; (E) 602 (B2) 1-methyl-1H-benzotriazole-6-yl; (E) 603 (B2) 2(1H)-quinolinone-4-yl; (E) 604 (B3) 2-pyridinyl; (E) 605 (B3) 1-methyl-2-pyrrolyl 606 (B2) 2,3,5,6-tetra(F)-4-(OC₂H₅)phenyl; (E) 607 (B2) 2,4-di(F)—C₆H₃; (E) 608 (B2) 3-Br-4-F—C₆H₃; (E) 609 (B2) 2-F-4-CF₃—C₆H₃; (E) 610 (B3) 4-NO₂—C₆H₄; (E) 611 (B16) 4-NH₂—C₆H₄; (E) 612 (B3) 4-(NHC(═O)CH₃)—C₆H₄; (E)

[0169] TABLE 14

Co No R¹, R⁴; stereochemical descriptor if (Ex No) not racemic and/or addition salt 613 (B1) 3-CF₃—C₆H₄; CH₃ 614 (B2) 3-CF₃—C₆H₄; CH₂C₆H₅ 615 (B1) 3-F—C₆H₄; CH₃ 616 (B1) 3-F—C₆H₄; CH₃ 617 (B2) 3-CF₃—C₆H₄; CH═CHC₆H₅; (E) 618 (B2) 3-F—C₆H₄; CH═CHC₆H₅; (E) 619 (B2) 3-F—C₆H₄; CH₂C₆H₅ 620 (B2) 3-F—C₆H₄; C(CH₃)═CHC₆H₅; (E); nitrate (1:1) 621 (B2) CH(C₂H₅)₂; 1,3-benzodioxolan-2-yl 622 (B1) CH₂C(CH₃)₃; CH₃ 623 (B2) CH₂C(CH₃)₃; CH₂(4-Cl—C₆H₄) 624 (B2) CH[C(═O)OC₂H₅]CH₃; CH₂(4-Cl—C₆H₄) 625 (B1) CH(CH₃)C₂H₅; CH₃ 626 (B2) CH(CH₃)C₂H₅; CH₂(4-Cl—C₆H₄) 627 (B1) CH[N(CH₃)₂]CH₃; CH₃; (A) 628 (B2) CH[N(CH₃)₂]CH₃; CH₂(4-Cl—C₆H₄); (A) 629 (B3) CH[N(CH₃)₂]CH₃; (CH₂)₂(3,4-diOCH₃—C₆H₃); (A) 630 (B3) CH[N(CH₃)₂]CH₃; CH₂(3,4,5-triOCH₃—C₆H₂); (A) 631 (B15) CH[N(CH₃)₂]CH₃; CH₃; (B) 632 (B2) CH[N(CH₃)₂]CH₃; C(CH₃)═CHC₆H₅; [A-(E)] 633 (B1) CH(CH₃)CH₂C₆H₅; CH₃ 634 (B2) CH(CH₃)CH₂C₆H₅; CH₂(4-Cl—C₆H₄) 635 (B15) 1-(methyl-1-piperidinyl)ethyl; CH₃ 636 (B2) 1-(methyl-1-piperidinyl)ethyl; CH₂(4-Cl—C₆H₄) 637 (B1) CH(CH₃)(n-C₃H₇); CH₃ 638 (B2) CH(CH₃)(n-C₃H₇); CH₂(4-Cl—C₆H₄) 639 (B3) CH(CH₃)(n-C₃H₇); CH₂(3,4-diOCH₃—C₆H₃) 640 (B3) CH(CH₃)C₂H₅: CH₂(3,4-diOCH₃—C₆H₃) 641 (B1) C(CH₃)₃; CH₃ 642 (B3) C(CH₃)₃; CH₂(3,4-diOCH₃—C₆H₃); hydrate (1; 1) 643 (B1) CH(n-C₃H₇)₂; CH₃ 644 (B2) CH(n-C₃H₇)₂; CH₂(3,4-diOCH₃—C₆H₃) 645 (B1) CH[N(CH₃)₂]C₂H₅; CH₃; (A) 646 (B3) CH[N(CH₃)₂]C₂H₅; CH₂(3,4-diOCH₃—C₆H₃); (A) 647 (B1) CH[N(C₂H₅)₂]CH₃; CH₃; (A) 648 (B1) CH[N(C₂H₅)₂]CH₃; CH₃; (A + B) 649 (B3) CH[N(C₂H₅)₂]CH₃; CH₂(3,4-diOCH₃—C₆H₃); (A)

[0170] TABLE 15

Co No R⁴, R^(b); stereochemical descriptor if (Ex No) not racemic and/or addition salt 650 (B2) H; H 651 (B2) H; 4-Cl 652 (B2) H; 3-Cl 653 (B2) H; 4-F 654 (B2) H; 3-CF₃ 655 (B2) C₆H₅; H 656 (B2) H; 3-F 657 (B2) CH₃; H 658 (B2) CH(CH₃)₂; H 659 (B2) cyclopentyl; H 660 (B2) C₂H₅; H 661 (B2) cyclohexyl; H 662 (B2) H; 4-OCH₃ 663 (B2) H; 4-OC₂H₅ 664 (B2) H; 2-Cl 665 (B2) H; 3-OCH₃ 666 (B3) H; 4-CH₃ 667 (B3) H; 3-OH 668 (B3) H; 4-OH 669 (B3) OH; 4-Cl 670 (B3) OCH₃; H; [R-(R*,R*)] + [R-(R*,S*)]

[0171] TABLE 16

R¹, R⁴; stereochemical Co No pyridinyl descriptor if not racemic (Ex No) position and/or addition salt 671 (B14) 3 CH(CH₃)₂; CH₃ 672 (B2) 3 C₆H₅; CH═CH—C₆H₅ 673 (B12) 3 4-Cl—C₆H₄; CH₃ 674 (B2) 3 4-Cl—C₆H₄; CH═CH—C₆H₅ 675 (B2) 3 C₆H₅; C(CH₃)═CH—C₆H₅ 676 (B2) 3 4-Cl—C₆H₄; CH═C(C₆H₅)₂ 677 (B3) 4 4-Cl—C₆H₄; CH═CC₆H₅)₂ 678 (B2) 3 3-F—C₆H₄; CH═CH—C₆H₅ 679 (B2) 3 CH(CH₃)₂; C(CH₃)═CH—C₆H₅; (E) 680 (B3) 2 4-Cl—C₆H₄; CH═C(C₆H₅)₂ 681 (B2) 4 CH(CH₃)₂; C(CH₃)═CH—C₆H₅; (E) 682 (B2) 2 CH(CH₃)₂; C(CH₃)═CH—C₆H₅; (E) 683 (B3) 3 4-Cl—C₆H₄; CH═CH(3-Cl—C₆H₄)₂ 684 (B3) 3 4-Cl—C₆H₄; CH═C(C₆H₅)(3-Cl—C₆H₄) 685 (B2) 4 CH(CH₃)₂; CH₂(4-Cl—C₆H₄) 686 (B3) 3 CH(CH₃)₂; CH₂(4-Cl—C₆H₄) 687 (B2) 2 CH(CH₃)₂; CH₂(4-Cl—C₆H₄) 688 (B13) 2 OH; CH₃ 689 (B13) 3 OH; CH₃ 690 (B31) 3 CH(CH₃)₂; NH(3-F—C₆H₄) 691 (B31) 2 CH(CH₃)₂; NH(3-F—C₆H₄) 692 (B31) 4 CH(CH₃)₂; NH(3-F—C₆H₄) 788 (B3) 4 H; CH═C(C₆H₅)(3-Cl—C₆H₄) 789 (B3) 4 CH(CH₃)₂; CH═C(C₆H₅)(3-Cl—C₆H₄) 790 (B3) 4 cyclohexyl; CH═C(C₆H₅)(3-Cl—C₆H₄)

[0172] TABLE 17

R¹, R⁴; stereochemical Co No methyl descriptor if not racemic (Ex No) position and/or addition salt 693 (B2) 5 4-Cl—C₆H₄; CH═C(C₆H₅)(3-Cl—C₆H₄); (E + Z) 694 (B1) 2 CH(CH₃)₂; CH₃ 695 (B2) 2 CH(CH₃)₂; CH₂(4-Cl—C₆H₄)

[0173] TABLE 18

Stereo- chemical descriptor if not racemic Co. Ex. and/or No. No. R¹ R⁴ X addition salt 696 B31 CH(CH₃)₂ CH₃ CH 697 B31 CH(CH₃)₂ C₆H₅ CH 698 B25 CH(CH₃)₂ C₆H₅—C(═O)— CH 699 B22a CH(CH₃)₂ H CH B22b 700 B31 CH(CH₃)₂ 2F—C₆H₄ CH 701 B31 CH(CH₃)₂ 3F—C₆H₄ CH 702 B25 CH(C₂H₅)₂ C₆H₅—C(═O)— CH 703 B22a CH(C₂H₅)₂ H CH 704 B27 CH(CH₃)[N(CH₃)₂] 2-benzothiazolyl CH (A) 705 B27 CH(C₂H₅)₂ 2-benzothiazolyl CH 706 B27 CH(C₂H₅)₂ 2-benzothiazolyl N 791 B25 2,5-diCl—C₆H₃ C₆H₅—C(═O)— CH 792 B22a 2,5-diCl—C₆H₃ H H

[0174] TABLE 19

Stereochemical Co. Ex. descriptor if No. No. (R^(a))_(n) R¹ X not racemic 707 B31 4-(O—C₂H₅) CH(CH₃)₂ CH 708 B23 3,4-di(OCH₃) CH(CH₃)₂ CH 709 B31 2,5-di(F) 3-(CF₃)—C₆H₄ CH 710 B31 2,5-di(F) CH(C₂H₅)₂ CH 711 B31 3-F 3-(CF₃)—C₆H₄ N 712 B31 2,5-di(F) CH(C₂H₅)₂ N 713 B31 2-F CH(C₂H₅)₂ CH 714 B31 2-F 3-(CF₃)—C₆H₄ CH 715 B31 2-F CH(C₂H₅)₂ N 716 B31 4-OCH₃ 3-(CF₃)—C₆H₄ CH 717 B23 3,4-di(OCH₃) CH(CH₃)[N(CH₃)₂] N (A) 718 B23 3,4-di(OCH₃) CH(C₂H₅)₂ N 719 B23 3,4-di(OCH₃) CH(CH₃)[N(CH₃)₂] CH (A) 720 B23 3,4-di(OCH₃) CH(CH₃)[N(CH₃)₂] N (B) 721 B23 3,4-di(OCH₃) CH₂—N(CH₃)₂ CH 722 B31 4-OCH₃ CH(CH₃)₂ CH 723 B31 3-F CH(C₂H₅)₂ N 724 B31 3-F CH(C₂H₅)₂ CH 725 B31 3-F CH(CH₃)₂ N 726 B31 2-F CH(CH₃)₂ CH 727 B7 3-NH₂ CH(CH₃)₂ CH 728 B31 2,5-di(F) CH(CH₃)₂ CH 729 B31 3-F 3-(CF₃)—C₆H₄ CH 730 B31 3-CF₃ CH(CH₃)₂ CH 731 B31 3-F 4-Cl—C₆H₄ CH 732 B31 3,4-di(Cl) CH(CH₃)₂ CH 733 B31 3-OCH₃ CH(CH₃)₂ CH 734 B31 2,4-di(F) CH(CH₃)₂ CH 735 B31 3-F C₆H₅ CH 736 B31 3-CH₃ CH(CH₃)₂ CH 737 B31 3-NO₂ CH(CH₃)₂ CH 738 B31 3-Cl CH(CH₃)₂ CH 739 B31 4-Cl CH(CH₃)₂ CH 740 B31 4-F CH(CH₃)₂ CH 741 B31 3-F CH(CH₃)₂ CH 742 B31 H CH(CH₃)₂ CH

[0175] TABLE 20

Stereochemical Co. No. descriptor if not (Ex. No.) R¹ R² R⁴ X Het racemic 743 (B29) CH(CH₃)₂ H NH₂ N—C₆H₅ 1H-1-imidazolyl 744 (B29) CH(CH₃)₂ H NH₂ N-(3F—C₆H₄) 1H-1-imidazolyl 745 (B2) CH(CH₃)₂ CH(CH₃)₂ —CH₂-(4-Cl—C₆H₄) O 1,2,4-triazol-1-yl 746 (B31) CH(CH₃)₂ CH(CH₃)₂ —NH-(3-F—C₆H₄) O 1H-1-imidazolyl 747 (B1) CH(CH₃)₂ CH(CH₃)₂ CH₃ O 1,2,4-triazol-1-yl 748 (B1) CH(CH₃)₂ H CH₃ O 1,2,4-triazol-4-yl 749 (B2) CH(CH₃)₂ H —C(CH₃)═CH—C₆H₅ O 1,2,4-triazol-4-yl 750 (B1) CH(CH₃)₂ CH(CH₃)₂ CH₃ O 1H-1-imidazolyl 751 (B2) CH(CH₃)₂ CH(CH₃)₂ —C(CH₃)═CH—C₆H₅ O 1H-1-imidazolyl (E) 752 (B17) CH₃ CH₃ CH₃ O 1H-1-imidazolyl 753 (B2) CH₃ CH₃ —C(CH₃)═CH—C₆H₅ O 1H-1-imidazolyl 754 (B1) CH(CH₃)₂ C₂H₅ CH₃ O 1H-1-imidazolyl 755 (B2) CH(CH₃)₂ C₂H₅ (4-Cl—C₆H₄)—CH₂— O 1H-1-imidazolyl 756 (B1) C₂H₅ C₂H₅ CH₃ O 1H-1-imidazolyl 757 (B1) CH(C₂H₅)₂ CH(CH₃)₂ CH₃ O 1H-1-imidazolyl 758 (B2) CH(CH₃)₂ C₂H₅ —C(CH₃)═CH—C₆H₅ O 1H-1-imidazolyl (E) 759 (B1) CH(CH₃)₂ CH₃ CH₃ O 1H-1-imidazolyl 760 (B1) CH(CH₃)₂ n-C₄H₉ CH₃ O 1H-1-imidazolyl 761 (B2) CH(CH₃)₂ n-C₄H₉ —C(CH₃)═CH—C₆H₅ O 1H-1-imidazolyl (E) 762 (B2) CH(CH₃)₂ CH(CH₃)₂ CH₂-[3,4-di-(OCH₃)—C₆H₃] 763 (B2) CH(CH₃)₂ CH(CH₃)₂ —CH₂-(4-Cl—C₆H₄) O 1H-1-imidazolyl 764 (B28) CH(CH₃)₂ H —CH₂-(4-Cl—C₆H₄) S 1H-1-imidazolyl 765 (B9) CH(C₂H₅)₂ n-C₃H₇ CH₃ O 1H-1-imidazolyl 766 (B2) CH(C₂H₅)₂ n-C₃H₇ —CH₂-(4-Cl—C₆H₄) O 1H-1-imidazolyl 767 (B1) CH(C₂H₅)₂ C₂H₅ CH₃ O 1H-1-imidazolyl 768 (B2) CH(C₂H₅)₂ C₂H₅ —CH₂-(4-Cl—C₆H₄) O 1H-1-imidazolyl 769 (B25) OH H CH₃ O

770 (B25) OH H CH₃ O

771 (B24) OH CH(CH₃)—N(CH₃)₂ CH₃ O 1-methyl-5-imidazolyl 772 (B24) OH CH(C₂H₅)₂ CH₃ O 1-methyl-5-imidazolyl 773 (B31) CH(CH₃)₂ H —NH-(3-F—C₆H₄) O 2-methyl-1-imidazolyl 793 (B33) 4-Cl—C₆H₄ H H O 1-methyl-5-imidazolyl 794 (B3) 4-Cl—C₆H₄ OH CH(OH)(3-Cl—C₆H₄) O 1-methyl-5-imidazolyl 795 (B3) 4-Cl—C₆H₄ H CH(OH)(3-Cl—C₆H₄) O 1-methyl-5-imidazolyl 796 (32) 2,5-diCl—C₆H₃ H —S—CH₃ NH 1H-1-imidazolyl 797 (B29) 2,5-diCl—C₆H₃ H —NH—CH₃ NH 1H-1-imidazolyl HCl (1:2)

[0176] TABLE 20

Co.No. (Ex.No.) R⁴ n 774 (B17) —CH₂—(4-Cl—C₆H₄) 3 775 (B17) CH₃ 3 776 (B17) CH₃ 4

[0177] TABLE 21 Comp Comp No. C H N No. C H N 17 64.0 6.2 12.7 466 75.6 6.3 12.6 18 63.8 6.3 13.0 467 76.9 7.0 11.7 20 63.5 6.7 12.8 468 80.8 6.8 9.0 21 64.2 6.6 12.8 469 77.4 6.5 11.7 30 72.3 8.3 8.4 470 77.8 7.1 10.8 52 72.0 8.1 9.3 471 77.6 7.7 10.9 53 68.7 8.6 12.2 472 78.2 7.5 10.1 61 74.2 8.2 10.0 482 77.2 7.6 10.8 64 65.9 5.8 16.3 483 73.5 6.0 9.1 85 70.8 7.7 13.8 484 73.7 6.2 9.1 86 70.7 7.8 13.9 485 81.8 5.9 8.6 87 69.6 6.7 10.6 497 78.7 5.6 10.8 119 71.3 7.5 10.0 502 75.9 6.6 12.0 120 75.1 7.0 8.4 511 79.7 6.4 9.9 121 74.4 6.9 11.9 512 72.8 5.2 9.6 122 73.9 7.9 10.2 513 74.8 6.2 8.9 123 74.0 7.9 10.3 514 75.2 6.2 8.4 125 74.3 8.1 10.0 515 73.7 5.8 9.1 131 64.7 5.7 15.2 521 69.9 7.4 16.3 142 69.6 6.8 11.0 523 70.0 5.2 13.6 143 62.7 5.2 10.3 524 63.4 4.5 11.7 145 71.4 7.0 15.2 566 67.6 8.1 18.6 147 72.1 7.0 15.4 572 76.2 7.1 12.7 148 52.6 5.0 11.5 574 71.4 7.7 14.0 152 72.3 7.2 16.0 575 73.3 6.8 15.6 154 73.5 6.8 15.7 576 73.2 6.7 15.6 162 66.9 5.9 14.0 577 69.5 6.0 10.6 163 70.2 7.8 15.3 578 67.3 5.6 9.8 164 76.9 7.6 11.6 579 69.7 6.1 10.5 194 71.0 6.4 17.5 580 67.4 5.6 9.8 237 70.6 6.5 10.7 581 75.6 8.6 11.4 247 71.7 6.6 16.6 582 73.7 7.0 10.7 248 69.4 5.6 11.5 583 73.3 6.4 11.1 259 50.5 4.3 16.5 584 73.4 7.0 10.5 260 50.6 4.4 16.6 585 72.9 6.4 11.1 298 60.1 6.0 16.5 586 72.9 6.4 11.1 299 60.7 6.0 16.5 587 76.4 7.5 10.6 318 68.2 7.3 13.5 588 74.1 8.6 13.2 343 68.9 6.5 14.8 589 77.2 7.4 11.2 348 69.6 7.5 12.7 602 68.6 6.2 19.8 349 65.1 8.2 22.5 612 71.9 6.8 13.5 360 69.3 6.6 10.5 613 59.8 4.2 15.3 367 67.0 6.2 14.3 614 65.9 4.4 12.7 368 65.1 6.2 13.8 615 65.8 4.9 18.2 369 67.5 5.1 8.9 616 65.7 4.7 18.2 376 62.7 4.5 8.3 617 66.9 4.1 12.4 383 69.4 7.6 12.1 618 72.1 4.7 14.0 389 69.5 7.5 11.0 619 71.3 4.9 14.6 391 67.2 7.1 11.7 620 64.5 4.7 14.2 392 68.3 7.4 12.7 636 66.0 6.6 14.9 394 64.8 6.2 9.0 644 67.4 7.3 11.5 397 66.2 6.3 10.3 650 75.1 6.8 12.5 402 64.6 6.5 9.6 666 76.1 7.4 11.9 404 67.9 6.9 9.8 667 71.9 6.5 11.9 405 67.9 7.0 9.7 676 79.3 5.1 5.5 410 66.9 7.2 11.8 677 79.8 5.1 5.5 411 69.8 7.1 12.1 679 80.8 7.0 7.4 414 68.9 7.6 12.1 680 78.9 5.0 5.6 415 71.6 7.2 10.8 681 81.4 7.2 7.5 417 71.2 6.0 9.0 682 80.8 7.1 7.5 419 75.1 6.4 9.5 695 68.0 6.2 10.7 420 75.2 5.5 11.0 704 60.3 5.7 18.7 425 72.9 5.1 10.2 705 63.3 6.2 15.7 426 72.9 5.5 9.6 706 60.5 5.4 19.2 438 65.5 7.2 16.1 720 61.5 6.6 19.3 445 79.6 5.9 10.7 734 64.8 5.4 15.2 454 79.9 6.3 10.0 749 73.4 6.7 15.6 455 77.0 7.0 11.7 771 63.9 7.7 17.2 456 79.5 6.7 9.5 777 65.1 5.6 17.2 457 77.3 7.4 11.2 782 70.6 7.7 13.9 458 76.5 7.1 11.5 783 70.5 7.7 13.8 459 76.3 7.1 11.5 786 67.0 4.5 8.9 460 75.4 6.6 12.0 788 76.0 4.9 6.5 461 72.0 6.0 11.3 789 76.9 5.8 5.9 462 77.0 7.3 11.2 793 66.1 4.9 12.7 463 78.1 7.4 10.4 794 61.8 4.4 8.4 464 77.1 7.6 10.7 795 63.5 4.6 8.6 465 77.5 7.8 10.4 797 46.9 4.6 14.5

[0178] C. Pharmacological examples

EXAMPLE C.1 Inhibition of retinoic acid (RA) metabolism

[0179] MCF-7 human breast cancer cells were grown as stock cultures according to art-known protocols. One day before the experiment, RA is added to the stock cultures to stimulate RA-metabolism. At the start of the experiment, cell suspensions were incubated in a tissue culture medium containing ³H-RA as the substrate. Different concentrations of the test compound (dissolved in 1% DMSO) were added to the incubation mixtures, and at the end of the incubation, the unmetabolized RA is separated from its polar metabolites. The fraction containing the polar ³H-labelled metabolites was collected and counted in a scintillation counter. For each experiment, a control and a blank incubation were run in parallel. Table 22 list the IC₅₀ value (defined as the concentration in M needed to reduce the amount of metabolites to 50% of the control) . TABLE 22 Co. IC₅₀ Co. IC₅₀ Co. IC₅₀ No. (in M) No. (in M) No. (in M) 1 1.38E-10 263 4.66E-09 711 >1.00E-07 2 3.00E-11 264 2.71E-09 712 4.30E-12 4 2.11E-09 266 3.11E-08 713 1.38E-09 5 2.70E-10 267 7.75E-09 715 1.54E-10 6 1.65E-09 268 7.79E-09 718 1.33E-10 7 7.90E-10 269 2.66E-09 722 4.14E-09 8 9.37E-11 270 5.61E-09 723 1.13E-09 10 1.55E-09 271 2.45E-09 724 1.18E-09 11 2.63E-09 272 4.81E-09 725 3.29E-09 12 3.65E-11 273 5.27E-08 726 3.71E-09 13 3.57E-11 274 6.64E-09 727 1.64E-09 17 9.99E-10 275 4.28E-09 728 1.41E-09 18 8.72E-10 276 1.60E-08 729 >1.00E-07 21 2.89E-09 277 1.17E-09 730 1.59E-08 22 1.04E-09 288 1.28E-09 731 >1.00E-07 23 5.03E-10 290 1.14E-09 732 1.93E-08 24 1.37E-09 291 4.23E-09 733 2.41E-09 25 6.10E-08 292 1.37E-10 734 2.25E-09 26 2.01E-10 293 6.53E-09 735 >1.00E-07 27 2.32E-10 297 7.86E-10 736 7.45E-09 28 2.76E-09 299 7.72E-10 737 2.36E-09 29 8.12E-09 301 6.05E-09 738 2.03E-09 30 2.58E-08 303 3.26E-09 739 4.21E-08 31 2.63E-09 305 8.29E-11 740 1.29E-09 32 6.97E-10 306 1.26E-09 741 1.44E-09 33 1.01E-09 307 7.01E-10 742 2.61E-10 34 1.03E-09 309 3.65E-09 743 1.10E-08 35 2.24E-09 311 6.64E-10 744 >1.00E-07 36 1.43E-09 313 2.00E-11 745 3.87E-09 37 1.00E-09 316 4.06E-09 746 >1.00E-07 38 1.04E-09 330 1.82E-09 749 1.26E-07 39 1.04E-10 332 1.50E-09 751 6.70E-08 41 1.98E-09 336 1.91E-09 753 >1.00E-07 45 1.72E-10 339 1.23E-09 755 4.35E-09 46 1.95E-09 346 2.04E-09 758 1.88E-09 47 1.33E-09 351 5.69E-09 761 >1.00E-07 48 5.69E-10 352 2.57E-10 762 4.08E-08 49 4.33E-10 353 1.97E-09 763 5.62E-09 50 7.44E-09 355 >1.00E-07 764 2.33E-08 51 8.95E-10 356 >1.00E-07 772 1.46E-10 52 9.07E-10 357 >1.00E-07 773 >1.00E-07 53 2.12E-09 358 >1.00E-07 774 5.27E-09 54 4.86E-09 359 6.25E-09 776 4.39E-09 56 2.51E-11 360 1.08E-09 778 7.59E-08 58 <1.00E-11 361 >1.00E-07 780 4.57E-09 61 7.34E-10 362 1.43E-08 781 3.24E-09 63 6.70E-09 363 1.42E-09 782 1.26E-09 64 6.60E-09 364 1.41E-09 783 3.98E-08 65 3.79E-10 365 1.08E-09 66 3.56E-10 366 3.05E-09 67 3.34E-10 367 1.25E-09 68 1.72E-09 368 5.83E-10 69 2.50E-10 369 8.22E-08 70 2.95E-10 370 8.34E-08 71 2.62E-10 371 3.59E-09 72 1.66E-09 372 1.97E-09 73 4.63E-10 376 <1.00E-10 75 4.17E-10 378 1.74E-09 76 5.88E-10 383 7.29E-10 77 3.32E-10 385 6.75E-09 78 2.27E-10 388 8.29E-10 79 3.42E-11 389 5.67E-11 80 4.83E-11 393 9.55E-10 81 2.31E-10 404 1.35E-09 82 1.16E-09 405 3.68E-09 83 1.62E-10 412 3.99E-09 84 1.74E-09 413 5.27E-09 85 3.92E-09 415 2.64E-09 86 4.97E-10 416 3.67E-10 87 2.80E-10 420 8.38E-08 88 1.48E-10 421 >1.00E-07 89 1.31E-10 422 >1.00E-08 90 2.36E-09 423 4.08E-08 91 9.35E-10 424 >1.00E-07 92 2.21E-09 425 3.81E-08 93 1.59E-09 426 >1.00E-07 94 1.06E-09 427 8.34E-09 95 1.48E-09 432 8.10E-10 96 1.09E-09 435 2.80E-09 97 1.32E-09 445 1.92E-07 98 1.64E-09 454 5.25E-08 99 5.77E-09 455 2.87E-09 102 6.78E-11 456 1.40E-07 103 7.11E-09 457 2.50E-08 104 4.07E-11 458 3.22E-09 105 5.16E-11 459 1.77E-08 106 1.69E-09 460 3.63E-08 107 1.44E-09 461 1.69E-08 108 2.34E-11 462 >1.00E-06 109 3.21E-10 463 2.45E-08 110 9.53E-10 464 1.49E-07 111 1.03E-09 465 5.04E-08 112 9.89E-10 466 >1.00E-06 113 8.52E-10 467 2.58E-09 115 8.17E-09 468 >1.00E-07 116 6.78E-10 469 >1.00E-07 117 2.55E-10 470 1.87E-08 118 2.24E-09 471 >1.00E-07 119 9.40E-10 472 9.51E-08 120 3.88E-09 473 >1.00E-07 121 9.14E-10 474 1.59E-08 122 2.40E-09 475 >1.00E-07 123 2.47E-11 476 3.55E-08 124 3.97E-11 477 >1.00E-06 125 1.94E-10 478 1.63E-09 126 <1.00E-11 479 >1.00E-07 127 2.85E-11 480 4.25E-09 128 1.81E-11 481 2.83E-09 129 2.36E-11 482 1.95E-09 130 1.09E-11 483 1.98E-08 131 4.10E-09 484 3.43E-09 132 4.49E-09 485 >1.00E-07 133 4.56E-09 486 2.77E-08 134 2.98E-09 488 >1.00E-07 135 1.43E-09 489 >1.00E-07 136 4.83E-09 490 >1.00E-07 137 1.85E-09 491 1.84E-09 138 6.38E-09 492 4.07E-09 139 1.75E-09 493 8.77E-09 140 2.15E-08 497 3.76E-08 141 1.31E-09 502 3.29E-08 142 3.11E-08 511 1.05E-08 143 4.08E-09 512 6.16E-07 145 3.03E-09 513 8.60E-07 147 3.30E-08 514 >1.00E-06 148 1.86E-09 515 >1.00E-06 151 2.11E-09 516 >1.00E-06 152 5.18E-09 517 3.69E-08 154 4.14E-09 518 >1.00E-07 155 5.01E-08 519 3.80E-09 156 3.10E-08 524 >1.00E-06 157 8.48E-08 558 1.32E-09 158 >1.00E-07 574 1.78E-09 159 >1.00E-07 575 2.57E-08 160 8.65E-08 576 2.01E-08 161 1.87E-09 577 4.23E-08 162 2.88E-09 578 7.67E-09 163 2.36E-09 579 1.24E-08 164 8.15E-09 580 3.13E-08 165 1.08E-08 581 >1.00E-07 166 1.75E-09 582 1.58E-09 167 4.16E-09 583 2.78E-09 168 2.36E-09 584 6.51E-09 169 5.31E-10 585 7.21E-09 170 1.22E-08 586 3.74E-09 171 8.58E-08 587 3.16E-08 172 3.41E-09 588 4.88E-08 173 5.17E-09 589 2.75E-09 174 1.60E-09 590 2.78E-09 175 4.83E-09 591 4.01E-08 176 1.87E-08 592 4.15E-09 179 3.69E-08 593 2.70E-09 180 5.69E-08 594 4.81E-09 181 1.41E-08 595 3.83E-09 182 1.31E-08 596 7.92E-09 183 7.40E-09 597 5.00E-09 184 5.15E-09 598 2.39E-08 185 3.97E-08 599 6.36E-09 186 >1.00E-07 600 3.67E-08 187 1.88E-08 601 2.00E-08 189 >1.00E-07 602 2.57E-08 190 >1.00E-07 603 >1.00E-07 191 >1.00E-07 604 2.89E-09 192 3.34E-09 605 1.40E-08 193 1.21E-08 606 1.36E-08 194 7.07E-09 608 6.61E-09 195 3.51E-08 609 1.09E-08 196 2.23E-08 610 6.53E-09 197 5.61E-09 611 3.42E-09 198 1.07E-08 612 1.68E-08 199 7.82E-09 613 1.80E-06 200 4.43E-08 614 2.78E-07 201 3.58E-09 615 >1.00E-06 202 1.84E-09 616 >1.00E-06 203 2.28E-08 617 1.51E-07 204 4.58E-09 618 1.57E-08 205 1.17E-08 619 3.57E-08 207 2.54E-08 620 >1.00E-06 208 6.43E-09 621 1.25E-09 209 8.27E-09 623 1.38E-09 210 2.90E-08 639 1.68E-09 212 4.07E-09 640 2.17E-09 213 2.07E-09 642 1.16E-09 214 3.37E-09 644 2.96E-10 215 3.60E-08 645 8.02E-09 216 1.17E-08 646 3.07E-09 217 5.14E-09 649 7.32E-09 219 3.20E-09 650 4.86E-09 220 1.48E-09 651 1.05E-08 221 1.08E-09 652 >1.00E-07 222 3.32E-09 653 1.34E-09 223 1.20E-09 654 2.34E-09 224 4.73E-09 655 1.61E-08 225 8.28E-08 656 1.47E-09 226 1.69E-08 657 5.36E-09 227 7.80E-09 658 5.48E-09 228 7.30E-08 659 >1.00E-07 229 1.64E-09 660 6.37E-09 230 3.89E-09 661 3.40E-08 231 1.86E-09 662 3.58E-10 232 1.51E-09 663 1.95E-09 233 2.43E-09 664 1.56E-09 234 3.01E-09 665 5.91E-09 235 6.94E-09 666 1.45E-08 236 9.84E-08 667 1.57E-09 237 1.82E-08 668 3.16E-09 238 >1.00E-07 669 8.66E-09 239 7.28E-10 670 5.72E-09 240 1.34E-09 679 >1.00E-06 241 2.59E-09 680 1.21E-08 242 2.82E-09 681 >1.00E-06 243 3.59E-08 682 >1.00E-07 244 2.30E-09 685 9.08E-08 245 2.79E-09 686 4.31E-08 246 2.10E-09 687 >1.00E-07 247 3.55E-08 690 >1.00E-07 248 1.79E-09 691 >1.00E-07 249 7.58E-08 692 3.80E-08 250 1.49E-08 693 >1.00E-07 251 3.93E-09 695 >1.00E-07 252 2.59E-09 696 8.07E-09 253 5.55E-09 697 1.71E-08 254 6.47E-09 698 3.96E-08 255 6.24E-09 699 9.69E-09 256 3.20E-09 700 1.20E-08 259 9.29E-09 707 1.30E-08 260 2.43E-09 708 1.61E-09 261 2.22E-09 709 2.40E-09 262 7.48E-09 710 1.88E-10

EXAMPLE C.2 “Vaginal Keratinization Test on Ovariectomized Rats”

[0180] Ovariectomized rats were injected subcutaneously with a sesame oil solution containing 100 μg of estradiol undecylate in a volume of 0.1 ml per 100 g body weight and control animals were injected with sesame oil. On day one, two and three, test animals were treated once daily with a per os dose of the test compound and control animals with the drug vehicle (PEG 200). One day after the last treatment, the animals were sacrificed and their vaginas were processed for histological evaluation according to the method described in J. Pharmacol. Exp. Ther. 261(2), 773-779 (1992). A dose at which 50% of the tested rats show complete suppression of the estradiol undecylate induced keratinization effects is defined as an active dose. Table 23 lists the lowest active dose (LAD in mg/kg)of the compounds of formula (I) which were tested. TABLE 23 Co. LAD Co. LAD Co. LAD Co. LAD No. (mg/kg) No. (mg/kg) No. (mg/kg) No. (mg/kg) 2 5.00 204 >10.00 409 5.00 679 >20.00 3 >2.50 205 >10.00 410 >5.00 680 >20.00 4 0.60 207 10.00 411 2.50 681 >20.00 5 >2.50 208 >10.00 412 >2.50 682 >20.00 6 2.50 209 5.00 413 5.00 686 >10.00 7 >2.50 210 20.00 414 5.00 690 >10.00 8 >2.50 212 20.00 416 >5.00 692 >10.00 10 2.50 213 20.00 417 >5.00 695 >10.00 11 >2.50 214 20.00 419 >5.00 696 >10.00 13 >2.50 215 20.00 420 >20.00 697 10.00 15 >2.50 216 20.00 421 >10.00 698 20.00 18 2.50 217 10.00 422 >10.00 700 5.00 20 2.50 219 20.00 423 20.00 704 >5.00 21 5.00 220 20.00 424 >10.00 705 >5.00 22 2.50 221 10.00 425 >10.00 706 5.00 23 2.50 222 20.00 426 >10.00 707 5.00 24 2.50 223 5.00 427 2.50 708 >5.00 25 10.00 224 >10.00 428 >2.50 709 5.00 26 5.00 227 >10.00 429 >2.50 710 2.50 27 5.00 228 >10.00 431 >2.50 711 5.00 28 2.50 229 >10.00 432 >2.50 712 5.00 29 5.00 230 >10.00 433 >2.50 713 2.50 30 >5.00 231 >10.00 434 >2.50 714 2.50 31 5.00 232 >10.00 435 >2.50 715 >2.50 32 5.00 233 >10.00 436 >5.00 716 >2.50 33 5.00 234 10.00 437 >2.50 717 >2.50 34 2.50 235 5.00 438 >2.50 718 2.50 35 2.50 236 5.00 439 >2.50 720 >2.50 36 5.00 237 5.00 445 >20.00 721 >2.50 37 5.00 238 5.00 454 >20.00 722 5.00 38 5.00 239 10.00 455 2.50 723 5.00 39 0.60 240 10.00 456 >20.00 724 2.50 41 2.50 241 10.00 457 >20.00 725 5.00 43 2.50 242 >10.00 458 5.00 726 5.00 44 2.50 243 10.00 459 20.00 727 >10.00 45 2.50 244 10.00 460 >20.00 728 5.00 46 >2.50 245 10.00 461 10.00 729 2.50 47 2.50 246 10.00 462 20.00 730 >10.00 48 2.50 247 10.00 463 20.00 732 >10.00 49 2.50 248 2.50 464 >20.00 733 >10.00 50 2.50 249 5.00 465 >20.00 734 10.00 52 2.50 250 >10.00 466 >20.00 735 10.00 53 >2.50 251 10.00 467 >20.00 736 >10.00 55 >2.50 252 >10.00 468 10.00 737 >10.00 56 >5.00 253 >5.00 469 >10.00 738 10.00 57 >5.00 254 >5.00 470 >20.00 739 >10.00 58 5.00 255 5.00 471 >10.00 740 20.00 59 >2.50 256 >2.50 472 >20.00 741 10.00 61 2.50 261 >10.00 473 >10.00 742 10.00 62 >5.00 262 20.00 474 >10.00 743 >10.00 63 >5.00 263 >10.00 475 >10.00 745 >5.00 64 >5.00 264 >10.00 476 >10.00 746 >5.00 65 5.00 266 >10.00 477 >10.00 749 >20.00 66 2.50 267 >10.00 478 2.50 751 10.00 67 2.50 268 >10.00 479 >10.00 753 >10.00 68 5.00 269 >10.00 480 10.00 754 10.00 69 2.50 270 >10.00 481 10.00 758 >5.00 70 5.00 271 10.00 482 10.00 761 >5.00 71 >5.00 272 >10.00 483 >5.00 762 >5.00 72 2.50 273 >10.00 484 >5.00 763 >5.00 73 >2.50 274 >10.00 485 5.00 764 >5.00 74 2.50 275 >10.00 486 5.00 766 >2.50 75 2.50 276 >10.00 487 >5.00 768 >2.50 76 >2.50 277 >5.00 489 2.50 772 >5.00 77 2.50 278 2.50 490 2.50 773 >10.00 78 1.25 279 2.50 492 >2.50 774 10.00 79 2.50 280 >2.50 493 >2.50 776 >20.00 80 >2.50 281 >2.50 494 >2.50 778 5.00 81 2.50 283 2.50 495 >2.50 782 2.50 82 2.50 284 2.50 497 >20.00 783 5.00 83 >2.50 285 >2.50 502 5.00 784 >5.00 84 >2.50 286 >2.50 511 >20.00 785 5.00 85 2.50 287 >2.50 512 >20.00 86 2.50 288 >2.50 513 >20.00 87 1.25 289 >2.50 514 >20.00 88 2.50 290 2.50 515 >20.00 89 2.50 291 >2.50 518 >10.00 90 2.50 292 >2.50 519 >10.00 91 2.50 293 >2.50 521 10.00 92 5.00 294 >2.50 524 20.00 93 2.50 295 >2.50 532 >10.00 94 5.00 297 >2.50 551 >2.50 95 5.00 300 >2.50 552 >2.50 96 2.50 301 >2.50 554 2.50 97 2.50 302 >2.50 555 >2.50 98 5.00 304 >2.50 557 >5.00 99 2.50 306 >2.50 558 >5.00 102 5.00 307 >2.50 560 >5.00 103 >2.50 308 >2.50 562 5.00 104 2.50 309 >2.50 566 5.00 105 2.50 310 2.50 570 >5.00 106 2.50 311 2.50 572 >5.00 107 >2.50 312 >2.50 574 20.00 109 2.50 313 2.50 575 20.00 110 >2.50 314 >2.50 576 10.00 111 >2.50 315 >2.50 577 10.00 112 2.50 316 5.00 578 >10.00 113 >2.50 317 >5.00 579 10.00 114 2.50 318 >2.50 580 10.00 115 >2.50 319 >5.00 581 20.00 116 2.50 320 5.00 582 >10.00 117 >2.50 322 >2.50 583 10.00 118 2.50 324 >2.50 584 10.00 121 >2.50 325 2.50 585 10.00 122 >2.50 326 >2.50 586 >10.00 123 2.50 327 >2.50 587 >10.00 125 2.50 328 >2.50 588 10.00 126 2.50 329 >2.50 589 10.00 127 >2.50 330 2.50 590 >10.00 128 5.00 332 >2.50 591 >10.00 129 2.50 333 >2.50 592 >10.00 130 5.00 337 2.50 593 >10.00 131 5.00 338 >2.50 594 >10.00 132 5.00 339 >2.50 595 10.00 133 >5.00 340 2.50 596 10.00 134 5.00 341 >2.50 597 >10.00 135 2.50 342 >2.50 598 >10.00 136 5.00 343 >2.50 599 >20.00 137 >5.00 346 >5.00 600 >10.00 138 >5.00 347 >5.00 601 10.00 139 10.00 348 >2.50 602 >10.00 140 5.00 349 >2.50 603 >10.00 141 >10.00 350 >2.50 604 >10.00 142 5.00 351 >5.00 605 >10.00 143 10.00 352 >5.00 606 >10.00 148 >5.00 353 >5.00 608 >10.00 151 5.00 354 >5.00 609 10.00 152 >5.00 355 >10.00 610 >10.00 154 5.00 356 >10.00 611 10.00 155 >10.00 357 >10.00 612 10.00 156 >10.00 358 >10.00 613 >20.00 157 >10.00 359 >10.00 614 >20.00 158 >10.00 360 2.50 615 >20.00 159 >10.00 361 10.00 618 >20.00 160 10.00 362 10.00 619 >20.00 161 >2.50 363 >10.00 621 1.25 162 >5.00 364 2.50 623 >5.00 163 20.00 365 10.00 624 >2.50 164 20.00 366 >10.00 626 2.50 165 >20.00 367 2.50 627 >2.50 166 5.00 368 2.50 628 >2.50 167 10.00 369 10.00 629 >2.50 168 10.00 370 >10.00 630 >2.50 169 10.00 371 10.00 631 >2.50 170 10.00 372 5.00 632 >2.50 171 >10.00 374 2.50 636 2.50 172 10.00 375 >5.00 638 >2.50 173 10.00 376 2.50 639 2.50 174 10.00 378 2.50 640 >2.50 175 10.00 379 >2.50 642 2.50 176 >10.00 380 >2.50 644 2.50 178 >10.00 381 >2.50 645 >5.00 179 >10.00 383 >2.50 646 5.00 180 >10.00 384 >2.50 647 >5.00 181 10.00 385 >2.50 649 5.00 182 10.00 386 >2.50 650 10.00 183 >10.00 387 >2.50 651 5.00 184 >10.00 389 >2.50 652 10.00 185 10.00 390 >2.50 653 5.00 186 >10.00 391 >5.00 654 5.00 187 >10.00 392 >5.00 655 >10.00 189 >10.00 393 5.00 656 10.00 190 >10.00 394 >2.50 657 >10.00 191 >10.00 395 >5.00 658 >10.00 192 >10.00 396 >2.50 659 >10.00 193 >10.00 397 >2.50 660 >10.00 194 10.00 398 >5.00 661 >10.00 195 >10.00 400 >2.50 662 5.00 196 >10.00 401 >2.50 663 2.50 197 >10.00 402 >5.00 664 5.00 198 >10.00 403 >5.00 665 2.50 199 >10.00 404 5.00 666 2.50 200 >10.00 405 5.00 667 5.00 201 >10.00 406 >5.00 668 5.00 202 >10.00 407 >5.00 669 5.00 203 >10.00 408 >5.00 670 >2.50

[0181] D. Composition examples

[0182] The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to animal and human subjects in accordance with the present invention. “Active ingredient” (A. I.) as used throughout these examples relates to a compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof.

EXAMPLE D.1

[0183] oral solution

[0184] 9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxy-benzoate were dissolved in 4 l of boiling purified water. In 3 1 of this solution were dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of A. I. The latter solution was combined with the remaining part of the former solution and 12 1 1,2,3-propane-triol and 3 1 of sorbitol 70% solution were added thereto. 40 g of sodium saccharin were dissolved in 0.5 1 of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 1 providing an oral solution comprising 5 mg of A. I. per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

EXAMPLE D.2

[0185] oral drops

[0186] 500 g of the A. I. was dissolved in 0.5 1 of 2-hydroxypropanoic acid and 1.5 1 of the polyethylene glycol at 60-80° C. After cooling to 30-40° C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 g of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 1, providing an oral drop solution comprising 10 mg/ml of A. I. The resulting solution was filled into suitable containers.

EXAMPLE D.3

[0187] capsules

[0188] 20 g of A. I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of A. I.

EXAMPLE D.4

[0189] injectable solution

[0190] 0.5 mg A. I. 1, 50 mg glucose anhydrous and 0.332 ml concentrated hydrochloric acid were mixed with 0.8 ml water for injections. Sodium hydroxide was added until pH=3.2±0.1 and water was added to 1 ml. The solution was sterilized and filled in sterile containers.

EXAMPLE D.5

[0191] film-coated tablets

[0192] A mixture of 100 g of the A. I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinyl-pyrrolidone (Kollidon-K 90 ®) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 g microcrystalline cellulose (Avicel ®) and 15 g hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

[0193] Coating

[0194] To a solution of 10 g methyl cellulose (Methocel 60 HG ®) in 75 ml of denaturated ethanol there was added a solution of 5 g of ethyl cellulose (Ethocel 22 cps ®) in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated color suspension (Opaspray K-1-2109 ®) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

EXAMPLE D.6

[0195] 2% cream

[0196] 75 mg stearyl alcohol, 2 mg cetyl alcohol, 20 mg sorbitan monostearate and 10 mg isopropyl myristate are introduced into a doublewall jacketed vessel and heated until the mixture has completely molten. This mixture is added to a separately prepared mixture of purified water, 200 mg propylene glycol and 15 mg polysorbate 60 having a temperature of 70 to 75° C. while using a homogenizer for liquids. The resulting emulsion is allowed to cool to below 25° C. while continuously mixing. A solution of 20 mg A. I., 1 mg polysorbate 80 and purified water and a solution of 2 mg sodium sulfite anhydrous in purified water are next added to the emulsion while continuously mixing. The cream, 1 g of the A. I. is homogenized and filled into suitable tubes.

EXAMPLE D.7

[0197] 2% topical gel

[0198] To a solution of 200 mg hydroxypropyl P-cyclodextrine in purified water is added 20 mg of A. I. while stirring. Hydrochloric acid is added until complete dissolution and then sodium hydroxide is added until pH 6.0. This solution is added to a dispersion of 10 mg carrageenan PJ in 50 mg propylene glycol while mixing. While mixing slowly, the mixture is heated to 50° C. and allowed to cool to about 35° C whereupon 50 mg ethyl alcohol 95% (v/v) is added. The rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.

EXAMPLE D.8

[0199] 2% topical cream

[0200] To a solution of 200 mg hydroxypropyl β-cyclodextrine in purified water is added 20 mg of A. I. while stirring. Hydrochloric acid is added until complete dissolution and next sodium hydroxide is added until pH 6.0. While stirring, 50 mg glycerol and 35 mg polysorbate 60 are added and the mixture is heated to 70° C. The resulting mixture is added to a mixture of 100 mg mineral oil, 20 mg stearyl alcohol, 20 mg cetyl alcohol, 20 mg glycerol monostearate and 15 mg sorbate 60 having a temperature of 70° C while mixing slowly. After cooling down to below 25° C., the rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.

EXAMPLE D.9

[0201] 2% liposome formulation

[0202] A mixture of 2 g A. I. microfine, 20 g phosphatidyl choline, 5 g cholesterol and 10 g ethyl alcohol is stirred and heated at 55-60° C. until complete dissolution and is added to a solution of 0.2 g methyl paraben, 0.02 g propyl paraben, 0.15 g disodium edetate and 0.3 g sodium chloride in purified water while homogenizing. 0.15 g Hydroxypropyl-methylcellulose in purified water ad 100 g is added and the mixing is continued until swelling is complete. 

1. A compound having the formula

a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein: X represents —O—, —S— or —NR³—; R¹ represents hydrogen, hydroxy, C₁₋₆alkyl or aryl; R² represents hydrogen; C₁₋₁₂alkyl; C₃₋₇cycloalkyl; C₂₋₈alkenyl; aryl; Het¹; or C₁₋₁₂alkyl substituted with one or two substituents selected from C₃₋₇cycloalkyl, hydroxy, C -4alkyloxy, cyano, amino, mono- and di(C₁₋₄alkyl)amino, mono- or di(arylC₁₋₄alkyl)amino, di(arylC₁₋₄alkyl)aminocarbonyloxy, (C₁₋₄alkyl) (arylC₁₋₄alkyl)amino, mono- and di(aryl)amino, (C₁₋₄alkyl)(di(C₁₋₄alkyl)-aminoC₁₋₄alkyl)amino, pyrrolidinyl, piperidinyl, piperazinyl optionally substituted with C₁₋₄alkyl, morpholinyl, perhydro-azepinyl, carboxyl, C₁₋₄alkyl-oxycarbonyl, aminocarbonyl, mono- and di(C₁₋₄alkyl)aminocarbonyl, aryl, aryloxy and arylthio; or R¹ and R² taken together may form a bivalent radical of formula —R¹—R²— wherein —R¹—R²— represents —(CH₂)_(n)— wherein n is 2, 3, 4, 5 or 6; R³ represents hydrogen, C₁₋₆alkyl, aryl, Het¹ or C₁₋₆alkyl substituted with aryl or Het¹; R⁴ represents hydrogen; hydroxy; mercapto; C₁₋₆alkyloxy; C₁₋₆alkylthio; aryloxy; arylthio; Het¹-oxy; Het¹-thio; C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-oxy, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonylC₁₋₆alkyl, carboxyl, C₁₋₆alkyloxy-carbonyl, arylC₁₋₆alkyloxy, arylC₁₋₆alkylthio, aryl, Het¹; C₂₋₈alkenyl optionally substituted with one, two or three substituents selected from halo, C₃₋₇cycloalkyl, aryl, Het¹; C₂₋₈alkynyl optionally substituted with halo, C₃₋₇cycloalkyl, aryl; C₃₋₇cycloalkyl optionally substituted with C₁₋₆alkyl or aryl; C₅₋₇cycloalkenyl optionally substituted with C₁₋₆alkyl or aryl; aryl; Het¹; or —Alk—NR³R⁵ (i) or —NR³R⁵ (ii) wherein Alk represents C₁₋₆alkanediyl; and R⁵ represents hydrogen, C₁₋₆alkyl, aryl, Het¹, (aryl or Het¹)C₁₋₆alkyl, (aryl or Hetl)carbonyl or (aryl or Het¹)C₁₋₆alkyloxycarbonyl; aryl represents indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl, phenyl; said indanyl, indenyl, naphtyl or phenyl may be substituted with one, two, three, four or five substituents each independently selected from hydroxy, halo, nitro, cyano, amino, azido, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl, polyhaloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, phenyl, phenyloxy, phenylC₁₋₆alkyloxy, pyridinylC₁₋₆alkyloxy, C₁₋₆alkyloxy, formyl, carboxyl and C₁₋₆alkylcarbonyl; or two adjacent carbon atoms on said phenyl may be substituted by a single bivalent radical having the formula C₁₋₁₂alkanediyl or polyhaloC₁₋₁₂alkanediyl; Het represents an unsaturated heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl and pyridinyl; each of said unsaturated heterocycles may optionally be substituted with amino, mercapto, C₁₋₆alkyl, C₁₋₆alkylthio or aryl; and Het¹ represents a monocyclic heterocycle selected from pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, 1,3,4-triazolyl, 1,2,4-triazolyl, tetrahydrofuranyl, furanyl, thiolanyl, thienyl, dioxolanyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, tetrahydropyranyl, pyranyl, morpholinyl and dioxanyl; each of said monocyclic heterocycles may be optionally substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl; or a bicyclic heterocycle selected from indolinyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, 2H-1-benzopyranyl, 3,4-dihydro-2H-1-benzopyranyl, benzthiazolyl, isoquinolinyl, quinolinyl, 3,4-dihydroquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, chromanyl, 1,4-benzodioxinyl, 1,4-benzoxathianyl, benzodioxanyl and benzodioxolanyl; each of said bicyclic heterocycles may be substituted with one or two substituents each independently selected from C₁₋₄alkyl, hydroxy, amino, halo, aryl, arylcarbonyl or C₁₋₄alkyloxycarbonyl.
 2. A compound as claimed in claim 1 wherein R¹ represents hydrogen, hydroxy or C₁₋₆alkyl; and R² represents hydrogen; C₁₋₁₂alkyl; C₃₋₇cycloalkyl; C₂₋₈alkenyl; aryl; Het¹; or C₁₋₁₂alkyl substituted with one or two substituents selected from hydroxy, C₁₋₄alkyloxy, cyano, mono- and di(C₁₋₄alkyl)amino, mono- or di(arylC₁₋₄alkyl)amino, di(arylC₁₋₄alkyl)aminocarbonyloxy, (C₁₋₄alkyl) (arylC₁₋₄alkyl)amino, (C₁₋₄alkyl)(di(C₁₋₄alkyl)aminoC₁₋₄alkyl)amino, piperidinyl, piperazinyl optionally substituted with C₁₋₄alkyl, morpholinyl, C₁₋₄alkyloxycarbonyl, aryl, aryloxy and arylthio; or R¹ and R² taken together may form a bivalent radical of formula —R¹—R²— wherein —R¹—R²— represents —(CH₂)_(n)— wherein n is
 2. 3. A compound according to claim 1 or 2 wherein R³ is hydrogen; X is O and R⁴ is aryl or C₁₋₁₂alkyl optionally substituted with one, two or three substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, C₁₋₆alkylthio, aryloxy, arylthio, Het¹-thio, C₃₋₇cycloalkyl optionally substituted with hydroxycarbonyl-C₁₋₆alkyl, carboxyl, C₁₋₆alkyloxycarbonyl, arylC₁₋₆alkylthio, aryl, Het¹; or a radical of formula (ii).
 4. A compound according to claim 1 or 2 wherein R³ is hydrogen, X is S and R⁴ is a radical of formula (ii).
 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in any one of the claims 1 to
 4. 6. A process of preparing a pharmaceutical composition as claimed in claim 5, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one of claims 1 to
 4. 7. A compound as claimed in any one of claims 1 to 4 for use as a medicine.
 8. Use of a compound as claimed in any one of claims 1 to 4 for the manufacture of a medicament for treating oncology disorders and keratinization disorders.
 9. A process of preparing a compound as claimed in claim 1, characterized by a) reacting an intermediate of formula (II) wherein W¹ is an appropriate leaving group with an intermediate of formula (III) or a functional derivative thereof in a reaction-inert solvent and in the presence of a suitable base;

and in case W¹ is an hydroxy group, in the presence of triphenylphosphine and diethyl azodicarboxylate or a functional derivative of any of said reagents, or in the presence of 1-hydroxy-1H-benzotriazole and dicyclohexylcarbodiimide; b) N-alkylation of an intermediate of formula (IV) with an intermediate of formula (V) wherein W² is an appropriate leaving group in a reaction-inert solvent and optionally in the presence of a suitable base; or

N-alkylation of an intermediate of formula (IV) with an anhydride, a cyanate, a thiocyanate, an isocyanate or an isothiocyanate optionally in the presence of an acid; c) reacting an intermediate of formula (VI) wherein W is a suitable leaving group with an intermediate of formula R^(4′)-H (VII) wherein R^(4′) is a Het¹C₁₋₁₂alkyl or a radical of formula (i) in a reaction-inert solvent in the presence of an appropriate base; thus forming compounds of formula (I-a);

d) reacting an intermediate of formula (VII) with Het-H (III) or a functional derivative thereof, in the presence of n-butyllithium or a flnctional derivative in a reaction-inert solvent and optionally in the presence of chlorotriethylsilane; thus obtaining compounds of formula (I) wherein R¹ is hydroxy, said compounds being represented by formula (I-b);

e) reacting a primary or secundary amine of formula (VIII) with an intermediate of formula (IX) in a reaction-inert solvent; thus obtaining compounds of formula (I) wherein R³ is hydrogen and R⁴ is attached by a nitrogen atom to the remainder of the molecule, said compounds being represented by formula (I-c);

f) reacting an intermediate of formula (XI) with Het-H (XII) or a functional derivative thereof, in a reaction-inert solvent; thus obtaining compounds of formula (I) wherein R² is optionally substituted hydroxymethyl, being represented by formula (I-d);

g) reacting an intermediate of formula (XIII) wherein W⁴ is a suitable leaving group with an intermediate of formula (XIV) in an appropriate solvent and in the presence of an acid;

h) reacting an intermediate corresponding to a compound of formula (I) wherein R² is LG-C₁₋₁₂alkyl wherein LG is an appropriate leaving group, with C₁₋₄alkylO⁻M⁺ wherein M⁺ is a suitable metal ion in a suitable solvent; thus obtaining compounds of formula (I) wherein R² is C₁₋₄alkyloxyC₁₋₁₂alkyl; i) reducing an intermediate of formula (XV) wherein R^(2′) is the same as R² being an optionally substituted C₁₋₁₂alkyl, using a suitable reducing agent in a suitable solvent; thus obtaining a compound of formula (I-e);

j) reacting an intermediate of formula (XXIII) with formnamide in the presence of an acid; thus forming a compound of formula (I-f);

and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms thereof.
 10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) an effective amount of retinoic acid, a derivative thereof or a stereochemically isomeric form thereof, and (b) an effective amount of a compound of formula (I) as described in any one of claims 1 to
 4. 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) an effective amount of calcitriol or a prodrug thereof, and (b) an effective amount of a compound of formula (I) as described in any one of claims 1 to
 4. 12. A product containing (a) a pharmaceutical composition containing an effective amount of retinoic acid, a derivative thereof or a stereochemically isomeric form thereof and a pharmaceutical acceptable carrier,, and (b) a pharmaceutical composition containing an effective amount of a compound of formula (I) as described in any one of claims 1 to 4, and a pharmaceutical acceptable carrier, as a combined preparation for simultaneous, separate or sequential use in dermatological or oncological disorders.
 13. A product containing (a) a pharmaceutical composition containing an effective amount of calcitriol or a prodrug thereof and a pharmaceutical acceptable carrier, and (b) a pharmaceutical composition containing an effective amount of a compound of formula (I) as described in any one of claims 1 to 4, and a pharmaceutical acceptable carrier, as a combined preparation for simultaneous, separate or sequential use in dermatological or oncological disorders.
 14. A product containing a) a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any of claims 1 to 4 and a pharmaceutically acceptable carrier; and b) a pharmaceutical composition comprising a pharmaceutically effective amount of an anti-neoplastic agent and a pharmaceutically acceptable carrier, as a combined preparation for simultaneous, separate or sequential use in dermatological or oncological disorders. 